var title_f14_49_15120="Automated DNA sequencing";
var content_f14_49_15120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Automated DNA sequencing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 195px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This representation of automated DNA sequencing shows how this technique can be used to detect mutations and other changes in DNA sequence. DNA is amplified in the presence of primers and chain terminators. Either the primers or the terminators are fluorescently labeled, with a different color fluorescence for each base. The automated sequencer uses a laser to excite the DNA containing these fluorescently labeled nucleotides and produces a color-coded intensity profile. In this example, guanine (G) is purple, adenine (A) is green, thymine (T) is red, and cytosine (C) is blue. The sequence can be read from the color of the peaks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15120=[""].join("\n");
var outline_f14_49_15120=null;
var title_f14_49_15121="Infantile myofibroma trunk";
var content_f14_49_15121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile myofibromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin-colored, firm nodules are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15121=[""].join("\n");
var outline_f14_49_15121=null;
var title_f14_49_15122="Cavitating bronchogenic ca CT";
var content_f14_49_15122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cavitating bronchogenic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The irregular internal wall contour and the wall thickness of the cavitating lesion are suggestive of malignancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15122=[""].join("\n");
var outline_f14_49_15122=null;
var title_f14_49_15123="Hgb H inclusions";
var content_f14_49_15123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hgb H inclusions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Red cells from a patient with acquired hemoglobin H disease were incubated in vitro with new methylene blue. Multiple (\"golf ball-like\") small inclusions due to precipitation of hemoglobin H are seen as a result of interaction with this dye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by Dr. German Pihan, Pathology Department, Beth Israel Deaconess Medical Center, Boston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15123=[""].join("\n");
var outline_f14_49_15123=null;
var title_f14_49_15124="Bisacodyl: Patient drug information";
var content_f14_49_15124=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bisacodyl: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"     see \"Bisacodyl: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/56/42883?source=see_link\">",
"     see \"Bisacodyl: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alophen&reg; [OTC];",
"     </li>",
"     <li>",
"      Bisac-Evac&trade; [OTC];",
"     </li>",
"     <li>",
"      Biscolax&trade; [OTC];",
"     </li>",
"     <li>",
"      Correctol&reg; Tablets [OTC];",
"     </li>",
"     <li>",
"      Dacodyl&trade; [OTC];",
"     </li>",
"     <li>",
"      Doxidan&reg; [OTC];",
"     </li>",
"     <li>",
"      Dulcolax&reg; [OTC];",
"     </li>",
"     <li>",
"      ex-lax&reg; Ultra [OTC];",
"     </li>",
"     <li>",
"      Femilax&trade; [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Bisacodyl [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Stimulant Laxative [OTC];",
"     </li>",
"     <li>",
"      Veracolate&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Bisacodyl&reg; [OTC];",
"     </li>",
"     <li>",
"      Bisacodyl-Odan [OTC];",
"     </li>",
"     <li>",
"      Bisacolax [OTC];",
"     </li>",
"     <li>",
"      Carter's Little Pills&reg; [OTC];",
"     </li>",
"     <li>",
"      Codulax [OTC];",
"     </li>",
"     <li>",
"      Dulcolax&reg; [OTC];",
"     </li>",
"     <li>",
"      PMS-Bisacodyl [OTC];",
"     </li>",
"     <li>",
"      ratio-Bisacodyl [OTC];",
"     </li>",
"     <li>",
"      Silver Bullet Suppository [OTC];",
"     </li>",
"     <li>",
"      Soflax [OTC];",
"     </li>",
"     <li>",
"      The Magic Bullett [OTC];",
"     </li>",
"     <li>",
"      Woman's Laxative [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bisacodyl or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bowel block, upset stomach, or throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dairy products, calcium, or magnesium within 1 hour of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly cramps.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository rectally.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10816 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15124=[""].join("\n");
var outline_f14_49_15124=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141443\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014777\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014776\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014781\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014782\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014784\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014779\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014780\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014785\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014786\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=related_link\">",
"      Bisacodyl: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/56/42883?source=related_link\">",
"      Bisacodyl: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_49_15125="Ramelteon: Drug information";
var content_f14_49_15125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ramelteon: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/29/22996?source=see_link\">",
"    see \"Ramelteon: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F854903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rozerem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F854907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hypnotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F854968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral: One 8 mg tablet within 30 minutes of bedtime",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F854969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F854970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F854971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required for mild-to-moderate impairment; use caution. Not recommended with severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F854972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rozerem&reg;: 8 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F854905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143463.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143463.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4040295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer with a high-fat meal. Swallow tablet whole; do not break.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F854908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of insomnia characterized by difficulty with sleep onset",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3121337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ramelteon may be confused with Remeron&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rozerem&reg; may be confused with Razadyne&reg;, Remeron&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F854917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (4% to 5%), somnolence (3% to 5%), fatigue (3% to 4%), insomnia worsened (3%), depression (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Serum cortisol decreased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (3%), taste perversion (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Myalgia (2%), arthralgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Anaphylaxis, angioedema, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls), prolactin levels increased, testosterone levels decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F854912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of angioedema with previous ramelteon therapy (do not rechallenge); concurrent use with fluvoxamine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F854913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abnormal thinking/behavioral changes: Hypnotics/sedatives have been associated with abnormal thinking and behavior changes including decreased inhibition, aggression, bizarre behavior, agitation, hallucinations, and depersonalization. These changes may occur unpredictably and may indicate previously unrecognized psychiatric disorders; evaluate appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression impairing physical and mental capabilities; patients must be cautioned about performing tasks, which require mental alertness (operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents (including ramelteon) for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema. Do not rechallenge patients who have developed angioedema with ramelteon therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reproductive hormonal regulation disturbances:  May cause disturbances of reproductive hormonal regulation (eg, disruption of menses or decreased libido).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression; worsening of depression, including suicidal ideation has been reported with the use of hypnotics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; use not recommended with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory compromise, COPD or sleep apnea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP1A2 inhibitors: Use with caution when administered concomitantly with strong CYP1A2 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after a reasonable period of treatment may indicate psychiatric and/or medical illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid onset: Because of the rapid onset of action, administer immediately prior to bedtime or after the patient has gone to bed and is having difficulty falling asleep.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F854924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C19 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F854923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F854927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May increase CNS depression. Management: Avoid or limit ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Taking with high-fat meal delays T",
"     <sub>",
"      max",
"     </sub>",
"     and increases AUC (~31%). Management: Do not take with a high-fat meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Some herbal medications may increase CNS depression. Management: Avoid valerian, St John's wort, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F854909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F854910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects. May cause disturbances of reproductive hormonal regulation (eg, disruption of menses or decreased libido). There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F854911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F854937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take with high-fat meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Rozerem Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $208.32",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Rozerem (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F854962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, selective agonist of melatonin receptors MT",
"     <sub>",
"      1",
"     </sub>",
"     and MT",
"     <sub>",
"      2",
"     </sub>",
"     (with little affinity for MT",
"     <sub>",
"      3",
"     </sub>",
"     ) within the suprachiasmic nucleus of the hypothalamus, an area responsible for determination of circadian rhythms and synchronization of the sleep-wake cycle. Agonism of MT",
"     <sub>",
"      1",
"     </sub>",
"     is thought to preferentially induce sleepiness, while MT",
"     <sub>",
"      2",
"     </sub>",
"     receptor activation preferentially influences regulation of circadian rhythms. Ramelteon is eightfold more selective for MT",
"     <sub>",
"      1",
"     </sub>",
"     than MT",
"     <sub>",
"      2",
"     </sub>",
"     and exhibits nearly sixfold higher affinity for MT",
"     <sub>",
"      1",
"     </sub>",
"     than melatonin, presumably allowing for enhanced effects on sleep induction.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F854964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid; high-fat meal delays T",
"     <sub>",
"      max",
"     </sub>",
"     and increases AUC (~31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 74 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~82%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism:  Extensive first-pass effect; oxidative metabolism primarily through CYP1A2 and to a lesser extent through CYP2C and CYP3A4; forms active metabolite (M-II)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Absolute: 1.8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Ramelteon: 1-2.6 hours; M-II: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Median: 0.5-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Primarily as metabolites: Urine (84%); feces (4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kato K, Hirai K, Nishiyama K, et al, \"Neurochemical Properties of Ramelteon (TAK-375), A Selective MT1/MT2 Receptor Agonist,\"",
"      <i>",
"       Neuropharmacology",
"      </i>",
"      , 2005, 48(2):301-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15125/abstract-text/15695169/pubmed\" id=\"15695169\" target=\"_blank\">",
"        15695169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nguyen NN, Uy SS, and Song JC, \"Ramelteon: A Novel Melatonin Receptor Agonist for the Treatment of Insomnia,\"",
"      <i>",
"       Formulary",
"      </i>",
"      , 2005, 40:146-55.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9475 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15125=[""].join("\n");
var outline_f14_49_15125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854907\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854968\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854969\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854970\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854971\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854972\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854905\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874968\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4040295\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854908\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3121337\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854917\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854912\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854913\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854924\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854923\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854927\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854909\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854910\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854911\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854937\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422157\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961925\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854962\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854964\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9475\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9475|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/29/22996?source=related_link\">",
"      Ramelteon: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_49_15126="Obstructed megaureter";
var content_f14_49_15126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraoperative picture of an obstructed megaureter with an aperistalic distal segment (black arrows)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15126=[""].join("\n");
var outline_f14_49_15126=null;
var title_f14_49_15127="An overview of allergen extracts";
var content_f14_49_15127=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   An overview of allergen extracts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/49/15127/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/49/15127/contributors\">",
"     J&oslash;rgen Nedergaard Larsen, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/49/15127/contributors\">",
"     Henning L&oslash;wenstein, PhD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/49/15127/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/49/15127/contributors\">",
"     Philip S Norman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/49/15127/contributors\">",
"     Peter S Creticos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/49/15127/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/49/15127/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/49/15127/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergens are molecules capable of eliciting an immune response that is characterized by the presence of specific immunoglobulin E (IgE) antibodies. Most allergens are proteins, and all foreign proteins are potential allergens.",
"   </p>",
"   <p>",
"    Not all antigen-specific IgE formed within the body gives rise to allergic disease. For example, antigens of parasitic origin induce specific IgE as part of the host's normal defensive response, but this immune response does not develop into allergic disease. Glycoproteins may induce specific IgE to either the peptide part or the carbohydrate moiety, or both. In most instances, IgE directed to the carbohydrate moiety is of low avidity and does not contribute to allergy in humans. However, there are a few rare exceptions mentioned in the literature, in which patients had severe reactions to glycoprotein allergens on biological drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergen extracts are complex mixtures of allergens, enzymes, other proteins, and compounds derived from natural allergen sources. They are used in a variety of applications, including diagnostic skin testing, provocation testing and in vitro tests, as well as allergen specific immunotherapy (both oral and subcutaneous). In all applications the active ingredient is, in principle, based on the same allergen extract. However, the formulation may differ between applications.",
"   </p>",
"   <p>",
"    The production and standardization of allergen extracts are discussed in this topic review. Specific applications are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergenic source materials include pollens, animal dander, fungal spores, house dust mite fecal particles, insect venoms, and foods. Allergen extracts are prepared by aqueous extraction of allergenic source materials obtained from natural sources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Components of allergen extracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen extracts are complex mixtures of allergens, enzymes including proteases, other proteins, and compounds derived from natural allergen sources. After processing, the active ingredient of an allergen extract is primarily a mixture of proteins, but other high molecular weight substances, such as polysaccharides, may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/2\">",
"     2",
"    </a>",
"    ]. Allergenic carbohydrate determinants are generally structural parts of glycoproteins. For batch-to-batch standardization, it is sufficient to consider the proteins as active ingredients.",
"   </p>",
"   <p>",
"    Aqueous allergen extracts represent an intermediate product, which can be used without further modification or subjected to further alterations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Major allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited number of allergens bind IgE antibodies in the serum of the majority of patients allergic to that allergen source. These molecules are called \"major allergens.&rdquo; A major allergen is defined as an antigen that binds to the IgE in the serum of &ge;50 percent of a clinically allergic group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/3\">",
"     3",
"    </a>",
"    ]. Other antigens, which account for &lt;50 percent of IgE binding, are called \"minor allergens\" (",
"    <a class=\"graphic graphic_picture graphicRef72410 \" href=\"UTD.htm?40/17/41247\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65499 \" href=\"UTD.htm?24/42/25263\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69136 \" href=\"UTD.htm?34/0/34830\">",
"     figure 2",
"    </a>",
"    ). A list of allergens important to human disease is maintained by the World Health Organization and the International Union of Immunologic Societies (WHO-IUIS) (",
"    <a class=\"external\" href=\"file://www.allergen.org/\">",
"     www.allergen.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H560880\">",
"    <span class=\"h3\">",
"     Proteases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen extracts also contain proteases capable of degrading the desirable allergens. Although these are unwanted, it is not possible to remove them without also destroying important allergenic proteins in the extract. The presence of proteases confers inherent instability to allergen extracts, which must be stored either freeze dried or stabilized by the addition of glycerol. Alternatively, chemical or physical modification can be applied. Stabilization based on chemical modification is usually performed by polymerization using aldehyde, whereas physical modification is performed by absorption to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Chemical modification'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Physical modification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     The paradox of extract refinement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen extracts are relatively crude mixtures of allergenic and nonallergenic molecules. This complexity mirrors the complexity of the allergen source as it is encountered during natural exposure. In addition to variability in the natural source of the allergen, there is variability among patients in their individual patterns of reactivity to the spectrum of allergens in a given source. Specifically, individuals do not respond to the same components in the allergen extract. As an example, although the major allergen in cat pelt, ie Fel d 1, is the most important allergen for over 90 percent of cat-allergic patients, a fraction of patients react more strongly to other allergens. In addition, most patients show significant reactivity to a large number of minor allergens in different combinations. This variability is even more pronounced for other allergen sources, such as grass pollen and house dust mite. Standardization is a process that ensures a comprehensive qualitative complexity in the allergen extract, in order to optimize effectiveness in diagnosis and treatment of a range of allergic individuals. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Standardization of allergen extracts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Quantitative aspects of an allergen extract are also important, especially for use in specific immunotherapy. For most allergen sources, one or two major allergens account for over 90 percent of the IgE binding, although patients may also react to various minor allergens. It is presently not clear whether treatment with one or two major allergens alone, such as has been proposed for recombinant allergens, will achieve efficacy comparable to treatment with current allergen extracts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44057?source=see_link&amp;anchor=H12#H12\">",
"     \"Future therapies for food allergy\", section on 'Engineered recombinant protein immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The challenge to industry and to investigators in the science of allergen extracts is to preserve the complexity of allergens in an extract, while enhancing the concentration of the individual allergens that are important to the majority of patients, and at the same time minimizing inert or unwanted pharmacologically-active components, as well as destructive protease activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H560777\">",
"    <span class=\"h2\">",
"     Selection of source materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of source materials should emphasize specificity and inclusion of all relevant allergens in sufficient amounts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/4\">",
"     4",
"    </a>",
"    ]. In some cases the optimal source material is relatively obvious, such as plant pollens and Hymenoptera venoms. Other substances, such as animal hair and dander, are more complicated. In both cat and mouse, for example, proteins derived from saliva and urine, respectively, are deposited in the fur as a result of the natural behavior of the animal. Although cat saliva and mouse urine would be suitable sources of potent allergens, they do not contain the full spectrum of allergens present in the particles to which humans are exposed, because proteins derived from fur also contain important allergens. Hair and dander collected by shaving, therefore, is the preferred source of allergenic animal material.",
"   </p>",
"   <p>",
"    Collection of the source materials should be performed by qualified personnel. The processing and storage of source materials should ensure that no unintended substances, including microbial organisms, are introduced into the materials. When possible, source materials should be fresh or stored in a manner that minimizes or prevents decomposition. Records should describe source materials in as much detail as possible, including the particulars of collection, pretreatment (eg, isolation of mite bodies or use of whole mite culture), and storage.",
"   </p>",
"   <p>",
"    Source materials collected in nature are subject to natural variation, which can be considerable. This problem is circumvented by analysis and mixing. Source materials are analyzed to verify antigen and allergen profiles, and differences in composition can then be leveled out by mixing source materials from different suppliers, different harvests, different years",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    different geographical regions. Dog extracts, for example, can be produced by mixing hair and dander from five different dog breeds. Subsequent standardization ensures that the variation in the final product is within predefined limits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H560784\">",
"    <span class=\"h2\">",
"     Preparation of aqueous allergen extracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen extracts are prepared by aqueous extraction of natural source materials. The production process is intended to be compatible with the physiological conditions to which the allergen is exposed upon contact with the human body. Allergens enter the body in various ways and encounter different physiologic conditions during the process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After ragweed pollen is inhaled, the particles penetrate into the airways, where they are extracted on the moist surface of the mucosa, liberating the allergenic molecules. These allergenic molecules are then taken up by antigen presenting cells and brought to immunological centers in lymph nodes.",
"     </li>",
"     <li>",
"      In the case of Hymenoptera venoms, the entire source material is injected directly into the human body through the skin.",
"     </li>",
"     <li>",
"      Food allergens must generally pass the acidic barrier of the stomach in order to reach the immunological centers in the intestine. Thus, food allergens must be resistant to the chemical and enzymatic degradation occurring in the stomach. Food allergens with structural similarities to pollen allergens are an exception to this generalization. Pollen-related food allergens can elicit symptoms in pollen-sensitized people while in contact with the oral mucosa, but are then destroyed in the stomach and usually do not cause systemic symptoms. This type of reaction underlies oral allergy syndrome, a type of food allergic reaction that is reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=see_link\">",
"       \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The extraction procedure should resemble the physiological conditions in the human body (ie, pH 6 to 9 and ionic strength 0.05 to 0.2) and must avoid denaturing the",
"    <span class=\"nowrap\">",
"     proteins/allergens",
"    </span>",
"    (ie, organic solvents should be excluded) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/5\">",
"     5",
"    </a>",
"    ]. The process should be quick and materials kept cold to avoid decomposition. Low-molecular-weight material (ie, below 5000 Da), which is primarily composed of nonallergenic pigments and salts, may also contain pharmacologically active substances and should be removed. The processing procedure should include assessment of known toxins, viral particles, microorganisms, free histamines, etc, verifying their concentration below defined thresholds.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For insect venoms, the raw venom may be used, although low molecular weight components should preferably be removed.",
"     </li>",
"     <li>",
"      Foods constitute a particularly diverse and difficult area, and the availability of standardized extracts is correspondingly limited. Foods are often derived from various cultivated varieties and subspecies grown under a broad variety of conditions. Differences in tissue distribution and solubility properties of individual allergens may prevent optimal yields in a single extraction procedure. In such cases, a superior extract is derived by combining extracts produced using different buffers and different tissues (eg, peel and pulp for fruits). Processing of the extract in an attempt to mimic digestion is specifically avoided, as some allergens causing oral allergy syndrome may be destroyed by such procedures. In addition, although some foods are typically cooked prior to ingestion, cooking unpredictably affects the allergenicity of the foods and so attempts are not made to recreate the effects of cooking in producing food extracts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Modification of extracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen extracts may be modified to enhance the",
"    <span class=\"nowrap\">",
"     efficacy/safety",
"    </span>",
"    ratio. This means that higher doses can be administered without compromising safety. Allergen extracts may be modified by chemical or physical modification, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chemical modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen extracts for use in immunotherapy may be chemically modified using formaldehyde or glutaraldehyde [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/6\">",
"     6",
"    </a>",
"    ]. The chemical reaction results in intra- and intermolecular cross-linking, which yields high-molecular-weight complexes (ie, allergoids). Chemical modification enhances the stability of the allergen extract. Although intended to reduce IgE binding while preserving immunogenicity, chemical modification, in practice, does not seem to increase safety [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/7\">",
"     7",
"    </a>",
"    ]. The likely explanation is that the chemical modification not only reduces allergenicity, but also immunogenicity, necessitating the use of higher doses.",
"   </p>",
"   <p>",
"    Other chemical modifications, such as coupling to biodegradable polymers, denaturation, fragmentation, or synthetic peptides representing individual allergens, have not shown adequate efficacy and safety in human immunotherapy trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Physical modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of allergen extracts coupled to inorganic gels, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    , increases the safety of immunotherapy through dual effects of the carrier. Coupling creates a depot effect, resulting in slow release of allergens to the tissue, and the gel provides an adjuvant effect, resulting in a more pronounced immune response to the vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Physical modification enhances the stability of the allergen extract. In Europe, most products for subcutaneous injection immunotherapy are absorbed to aluminum hydroxide.",
"   </p>",
"   <p>",
"    Coupling is performed simply by mixing the intermediate product (IMP) with the gel for a few minutes at room temperature. Coupling conditions need to be empirically determined for each extract, as the binding capacity of individual proteins varies with buffer composition, ionic strength, pH, and additives [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/12\">",
"     12",
"    </a>",
"    ]. Residual unbound protein must be verified to be below predefined thresholds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Molecular modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches to modification based on molecular and structural biology have shown promise, although these are largely limited to research at present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Additives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various additives may be added to allergen extracts. Bacteriostatic compounds are added to liquid allergen extracts to prevent growth of bacteria. Phenol (0.25 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    (20 percent) is used in this capacity. Glycerin (50 percent) is added to skin test products in order to increase the surface tension to allow drops to stay on the skin and not drain away. Tablets contain carriers, eg carbohydrate, etc, to maintain texture. Products for provocation testing (more commonly performed in Europe than in the US) are freeze dried for stability and generally do not contain additives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     STANDARDIZATION OF ALLERGEN EXTRACTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of standardization is to minimize the variation in composition, qualitative as well as quantitative, of the active ingredients (ie, allergens) in the final allergen extract. All aspects of the manufacturing procedure, from selection and collection of raw materials, to extract preparation and storage, as well as validation of assays and reagents for batch-to-batch control, influence vaccine quality and are considered part of the standardization procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standardized allergen products have documented composition and potency. However, different standardization procedures are in effect and there are no international standards of worldwide acceptance. Standardization is therefore a relative term with different meanings, particularly when comparing the United States (US) and Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3691361\">",
"    <span class=\"h2\">",
"     Batch-to-batch standardization",
"    </span>",
"    &nbsp;&mdash;&nbsp;An optimal standardization procedure should assess the following three elements on each and every batch:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complexity of the extract, ensuring the presence of all relevant allergens",
"     </li>",
"     <li>",
"      Major allergen content, ensuring that the most important allergens are present in sufficient amounts",
"     </li>",
"     <li>",
"      Overall potency (ie, IgE binding), ensuring a constant biological activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The complexity of the extract and the content of selected major allergen(s) can be determined using stable reagents. In contrast, determinations of potency require tests performed on a group of patients allergic to the substance in question. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Units that reflect potency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is not feasible to perform in vivo testing as a part of batch-to-batch control. Instead, standards are employed that have biologic activity defined by in vivo skin testing in a panel of allergic individuals. The properties of the standard must be described in great detail. Ideally, the standard should also prove useful in clinical trials of specific immunotherapy. Batch-to-batch control can then be performed using scientifically based in vitro methods comparing individual batches to the standard [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Batch-to-batch standardization is performed differently in the United States (US) compared with Europe:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the US, the Food and Drug Administration (FDA) provides standards and assays to be used in batch release. Demonstration of compliance with the FDA standard by assessment of complexity and overall potency is sufficient for batch release.",
"     </li>",
"     <li>",
"      In Europe, the manufacturers establish their own in-house reference preparations for batch release. Batch release is dependent on the demonstration of compliance with the in-house reference with respect to the assessment of complexity and overall potency as well as major allergen content when possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Standards and reference preparations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     US reference standards",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US FDA, through the Center for Biologics Evaluation and Research (CBER), has developed official standards that must be used in the manufacturing of standardized extracts within the US [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/16\">",
"     16",
"    </a>",
"    ]. FDA standards have been developed for pollens (grass, ragweed), cat, house dust mite, and insect venoms. Extracts produced using these standards are referred to as \"standardized\" extracts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     In-house reference preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, each manufacturer develops its own in-house reference preparation (IHRP), according to the guidelines established in the European Pharmacopoeia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The IHRP must be thoroughly characterized by laboratory methods as well as in vivo skin test potency measurements, and ideally also prove useful in clinical trials of immunotherapy, although the latter is not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Purified allergens as standards",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO-IUIS Allergen Standardization Subcommittee has taken an initiative (the CREATE Project) to develop certified reference materials (CRMs) based on purified natural and recombinant allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/20\">",
"     20",
"    </a>",
"    ]. ELISA assays for allergen measurement will also be evaluated and validated. Other methods with superior precision, such as mass spectrometry, could also be considered for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/21\">",
"     21",
"    </a>",
"    ]. Providing international allergen references and reference assays allows for a common system of units in absolute mass units of major allergen.",
"   </p>",
"   <p>",
"    However, a system based on labeling with major allergen content alone does not take into account the heterogeneity of individual patients' responses with variable reactivity to minor allergens, and thus, does not obviate the need for overall potency determinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     UNITS OF MEASURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen extracts are complex, and since extracts of different composition cannot be compared directly, several units of measure are in use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Units that do not reflect potency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some nonstandardized extracts are labeled in units that have no relation to allergenic potency. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protein nitrogen units (PNU): PNU is a measure of total protein content and does not distinguish between allergenic and nonallergenic proteins.",
"     </li>",
"     <li>",
"      Weight to volume ratio",
"      <span class=\"nowrap\">",
"       (w/v):",
"      </span>",
"      <span class=\"nowrap\">",
"       w/v",
"      </span>",
"      is the ratio of the weight (in grams) of the source material to the volume (in mL) of extraction fluid used to produce the extract. As an example, a 1:100 extract of oak pollen is produced by adding 1 gram of oak pollen to 100 mL of extraction diluent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These units are relatively uninformative because two extracts of the same allergen, labeled as the same strength in PNU or",
"    <span class=\"nowrap\">",
"     w/v,",
"    </span>",
"    may not be of equivalent potency if produced by different manufacturers. Thus, these units of measure are gradually being replaced by units that provide information about potency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Units that reflect potency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the potency of an allergen extract is complicated, due to the intrinsic variability among patients, as well as among naturally occurring plant and animal products, combined with the fact that different allergens are important to individual patients. Thus, potency is ultimately determined based upon tests performed on a group of patients allergic to the substance in question, or on serum derived from such patients. A variety of other units are used by different companies worldwide. Most company-specific units are based upon skin testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Biological unit (BU)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, the potency unit is based on the dose of allergen extract resulting in a wheal comparable in size to the wheal produced by a given concentration of histamine, in a group of patients allergic to the substance in question. This unit was originally called histamine equivalent potency (HEP); however, in the Nordic Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/22\">",
"     22",
"    </a>",
"    ], the unit is termed the biological unit (BU). The BU is not used in the market, as each manufacturer uses company-specific units based on in-house reference preparations. This means that in Europe, the potency of allergen extracts from different manufacturers cannot be compared, as they have different composition. Instead the clinical documentation for each product should be compared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Bioequivalent allergy unit (BAU)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, the FDA and CBER endorse the bioequivalent allergy unit (BAU). Standardized extracts are most commonly labelled in BAU.",
"   </p>",
"   <p>",
"    The method for assigning BAU is named the ID50EAL method (ie, Intradermal Dilution for 50 mm sum of Erythema diameters determines bioequivalent Allergy units) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15127/abstract/23\">",
"     23",
"    </a>",
"    ]. This method involves preparing a series of threefold dilutions of an extract and administering 0.5 mL intradermally to 15 to 20 highly allergic individuals. The dilution that induces an area of erythema with the sum of the longest diameter and midpoint (orthogonal) diameter equaling 50 mm is the D50. The mean D50 for the group is then assigned a potency in BAUs.",
"   </p>",
"   <p>",
"    The advantage of the system used in the US is greater transparency, as all manufacturers have to comply with the FDA standards and extracts can be labeled in common units. The advantage of the European system is greater flexibility, encouraging technical improvements and competition among manufacturers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen extracts are complex mixtures of allergenic and nonallergenic proteins, glycoproteins, polysaccharides, proteases, and small molecular weight substances, extracted in an aqueous diluent from natural allergen sources. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most allergens are proteins. No structural properties have been identified that distinguish allergenic from nonallergenic proteins, and all foreign proteins are potential allergens. Despite this, only a few proteins, called major allergens, are responsible for the majority of binding of IgE antibodies in the serum of allergic patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Components of allergen extracts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Crude extracts may be modified in various ways to prevent allergen degradation and bacterial growth, and increase potency and safety. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Modification of extracts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Batch-to-batch standardization of allergen extracts should include the following three elements:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ensuring that all relevant allergens are present",
"     </li>",
"     <li>",
"      Ensuring that the major allergens are present in sufficient amounts",
"     </li>",
"     <li>",
"      Ensuring the biologic potency is sufficient and accurately expressed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although some of the most commonly administered allergen extracts are now standardized, the majority of commercially available extracts are not. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Standardization of allergen extracts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several different units of measure are currently in use. Standardized extracts are preferred. These are generally labeled in either in company-specific units (Europe) or in BAU (United States). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Units of measure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DISCLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dr. Larsen is employed in the Management of Research and Development at ALK",
"    <span class=\"nowrap\">",
"     A/S,",
"    </span>",
"    a worldwide manufacturer of allergenic extracts. Dr. L&oslash;wenstein has retired from ALK",
"    <span class=\"nowrap\">",
"     A/S.",
"    </span>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/1\">",
"      Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/2\">",
"      Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/3\">",
"      King TP, Hoffman D, L&oslash;wenstein H, Marsh DG, Platts-Mills TAE, Thomas W. Allergen Nomenclature, J Allergy Clin Immunol 1995; 96:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/4\">",
"      L&oslash;wenstein H. Selection of reference preparation. IUIS reference preparation criteria. Arb Paul Ehrlich Inst 1987; 80:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/5\">",
"      L&oslash;wenstein H, Marsh DG. Antigens of Ambrosia elatior (short ragweed) pollen. I. Crossed immunoelectrophoretic analyses. J Immunol 1981; 126:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/6\">",
"      Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981; 68:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/7\">",
"      L&uuml;deritz-P&uuml;chel U, Keller-Stanislawski B, Haustein D. Neubewertung des Risikos von Test- und Therapieallergenen. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2001; 44:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/8\">",
"      Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/9\">",
"      Butler NR, Voyce MA, Burland WL, Hilton ML. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Br Med J 1969; 1:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/10\">",
"      Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/11\">",
"      Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/12\">",
"      al-Shakhshir RH, Regnier FE, White JL, Hem SL. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1995; 13:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/13\">",
"      Akdis CA, Blaser K. Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol 2000; 121:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/14\">",
"      Ferreira F, Briza P, Inf&uuml;hr D, et al. Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 2006; 5:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/15\">",
"      Larsen JN, Houghton CG, Vega ML, L&oslash;wenstein H. Manufacturing and standardizing allergen extracts in Europe. Clin Allergy Immunol 2008; 21:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/16\">",
"      Slater JE. Standardized allergen vaccines in the United States. Clin Allergy Immunol 2008; 21:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/17\">",
"      L&oslash;wenstein H. Physico chemical and immunochemical methods for the control of potency and quality of allergenic extracts. Arb Paul Ehrlich Inst 1980; 75:122.",
"     </a>",
"    </li>",
"    <li>",
"     Council of Europe. European Pharmacopoeia. European Treaty Series 50, Strasbourg, France, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/19\">",
"      Kaul S, May S, L&uuml;ttkopf D, Vieths S. Regulatory environment for allergen-specific immunotherapy. Allergy 2011; 66:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/20\">",
"      van Ree R, Chapman MD, Ferreira F, et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008; 63:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/21\">",
"      Sepp&auml;l&auml; U, Dauly C, Robinson S, et al. Absolute quantification of allergens from complex mixtures: a new sensitive tool for standardization of allergen extracts for specific immunotherapy. J Proteome Res 2011; 10:2113.",
"     </a>",
"    </li>",
"    <li>",
"     Nordic Council on Medicines. Registration of Allergen preparations: Nordic Guidelines. NLN Publication No 23, 1989, p. 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15127/abstract/23\">",
"      Turkeltaub PC. Biological standardization based on quantitative skin testing--the ID50 EAL method (intradermal dilution for 50 mm sum of erythema diameters determines the allergy unit). Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M 1987; :169.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 363 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15127=[""].join("\n");
var outline_f14_49_15127=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Components of allergen extracts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Major allergens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H560880\">",
"      - Proteases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      The paradox of extract refinement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H560777\">",
"      Selection of source materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H560784\">",
"      Preparation of aqueous allergen extracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Modification of extracts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chemical modification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Physical modification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Molecular modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      STANDARDIZATION OF ALLERGEN EXTRACTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3691361\">",
"      Batch-to-batch standardization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Standards and reference preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - US reference standards",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - In-house reference preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Purified allergens as standards",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      UNITS OF MEASURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Units that do not reflect potency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Units that reflect potency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Biological unit (BU)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Bioequivalent allergy unit (BAU)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DISCLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/363\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/363|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/42/25263\" title=\"figure 1\">",
"      Cat allergogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/0/34830\" title=\"figure 2\">",
"      Complexity of IgE response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/363|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/17/41247\" title=\"picture 1\">",
"      CRIE cat allgn extr",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44057?source=related_link\">",
"      Future therapies for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_49_15128="Candida infections of the bladder and kidneys";
var content_f14_49_15128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Candida infections of the bladder and kidneys",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/49/15128/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/49/15128/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/49/15128/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/49/15128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/49/15128/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/49/15128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/49/15128/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/49/15128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Funguria is common in hospitalized patients, and is generally benign. Invasive infection of the kidney is unusual, and is difficult to treat. The vast majority of fungal infections of the kidney and bladder result from Candida albicans and other Candida species. A variety of other fungi can rarely involve the kidney as a result of disseminated infection. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aspergillus species",
"     </li>",
"     <li>",
"      Fusarium species",
"     </li>",
"     <li>",
"      Trichosporon species",
"     </li>",
"     <li>",
"      Mucorales (eg, Rhizopus, Mucor species)",
"     </li>",
"     <li>",
"      Dematiaceous molds",
"     </li>",
"     <li>",
"      Cryptococcus neoformans",
"     </li>",
"     <li>",
"      Dimorphic fungi (eg, Histoplasma capsulatum, Coccidioides species, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Sporothrix schenckii, and Penicillium marneffei)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of Candida infections of the bladder and kidney will be presented here. Issues related to fungal peritonitis in patients treated with continuous peritoneal dialysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"     \"Fungal peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mice or rabbits infected intravenously with fungi clear these organisms quickly from their bloodstream. Despite this ability, fungal multiplication is commonly found within the kidney, the only organ in which this appears to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/1\">",
"     1",
"    </a>",
"    ]. Whether fungi preferentially localize in the kidney or are cleared from other organs more efficiently by host defense mechanisms is not understood.",
"   </p>",
"   <p>",
"    In these animal models, the two key steps in the pathogenesis of fungal renal infection are the attachment of fungi to endothelial surfaces and penetration into tissue. Within five minutes of injection, yeast forms are found in the capillary beds of the kidneys. Since this elicits an inflammatory response, yeasts survive only if they penetrate the capillary walls and invade the interstitium. Invasion is expedited by attachment to the capillary walls via adherence mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/2\">",
"     2",
"    </a>",
"    ]. Penetration through the capillary walls is facilitated by the formation of pseudohyphal or hyphal forms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The less common mechanism of ascending infection of the kidneys is thought to result from vesicoureteral reflux of fungi from the bladder. However, this mechanism is difficult to demonstrate in animal models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candiduria is a common event in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/4\">",
"     4",
"    </a>",
"    ], and the incidence appears to be increasing. In a report from the National Nosocomial Infections Surveillance System, the percentage of nosocomial urinary tract infections due to Candida species increased from 22 percent for the period 1986 to 1989 to almost 40 percent for the period of 1992 to 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/5\">",
"     5",
"    </a>",
"    ]. However, since many of the patients with funguria did not have symptoms, it is unclear if the urinary findings in this report represented infection versus colonization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective multicenter surveillance study evaluated 861 hospitalized patients with candiduria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/6\">",
"     6",
"    </a>",
"    ]. Candida albicans was found in 52 percent of these patients and Candida glabrata in 16 percent. The following risk factors were noted: urinary tract drainage devices (83 percent); prior antibiotic therapy (90 percent); diabetes (39 percent); urinary tract pathology (38 percent) and malignancy (22 percent). Only 11 percent had no underlying predisposing factors for funguria. Urinary tract infections associated with drainage devices, diabetes, or urinary tract abnormalities are considered complicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INFECTION VERSUS COLONIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with candiduria are asymptomatic, and the yeasts merely represent colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/5\">",
"     5",
"    </a>",
"    ]. However, it is difficult to differentiate between colonization and bladder infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infected patients may have dysuria, frequency, and suprapubic discomfort, but others have no symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pyuria is so common in patients with a chronic indwelling bladder catheter that it cannot be used to indicate infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"       \"Urinary tract infection associated with urethral catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neither the presence of pseudohyphae in the urine nor the number of colonies growing in culture (unlike bacterial urine cultures) help to distinguish colonization from infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic modalities used to distinguish infection from colonization are discussed below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several concerns in patients with asymptomatic candiduria: the development of ascending infection of the kidney, the development of candidemia, and the possibility that candiduria is a manifestation of disseminated candidiasis. These complications should be considered in the appropriate host:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ascending involvement of the kidneys usually occurs in the setting of urinary tract obstruction.",
"     </li>",
"     <li>",
"      Candiduria as a source of candidemia typically occurs in patients who have urinary tract abnormalities, most often urinary tract obstruction,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have undergone a urinary tract procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/7\">",
"       7",
"      </a>",
"      ]. In a review of 26 cases, two of five deaths were attributable to candidiasis with no late complications of candidemia in the survivors [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The kidneys are the most commonly involved organ in disseminated candidiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/8\">",
"       8",
"      </a>",
"      ]. Although candiduria can be seen in systemic infection, it is usually accompanied by many other signs and symptoms of disseminated infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal transplantation was previously thought to be a risk factor for ascending infection and candidemia when candiduria was present. A nested case-control study of 192 renal transplant recipients who developed candiduria was performed to assess the epidemiology of candiduria in a large population of 1738 transplant recipients over an eight-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/9\">",
"     9",
"    </a>",
"    ]. The study demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk factors for developing candiduria were similar to those described for nontransplant patients in prior studies [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Candidemia occurred in only five percent of patients with candiduria.",
"     </li>",
"     <li>",
"      Treatment with an antifungal agent did not result in a greater likelihood of clearing Candida from the urine when compared with simple catheter removal.",
"     </li>",
"     <li>",
"      Treatment of candiduria was not associated with a greater survival benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical characteristics of fungal kidney infections depend on whether the disease presents secondary to candidemia or from an ascending bladder infection. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Candidemia-associated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the kidney associated with candidemia is usually bilateral, consisting of multiple microabscesses in the cortex and medulla (",
"    <a class=\"graphic graphic_picture graphicRef52139 \" href=\"UTD.htm?37/49/38672\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The kidney is the most common organ involved in systemic Candida infections. This was illustrated in a review of 45 autopsies of patients with disseminated candidiasis: 40 had histological evidence of renal involvement compared with 26 with evidence of invasion of the heart, the next most commonly involved organ [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When present, symptoms and signs referable to renal infection include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flank",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdominal pain",
"     </li>",
"     <li>",
"      Costovertebral angle tenderness",
"     </li>",
"     <li>",
"      Abdominal tenderness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, kidney infection in premature neonates may be associated with severe manifestations; polymorphonuclear leukocytes in these hosts may not ingest and kill the yeast normally [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Urinary tract infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal function is only rarely compromised in adults. In neonates, however, there seems to be a higher propensity for fungus ball formation with resulting obstruction and serious renal impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Papillary necrosis can occur and the sloughed papillae may serve as a nidus for fungus ball formation. Although it is uncommon for Candida to invade vascular structures and cause infarction, there are reports of renal infarction secondary to emboli in patients with Candida endocarditis.",
"   </p>",
"   <p>",
"    Emphysematous pyelitis or pyelonephritis, characterized by air in the collecting system or renal parenchyma, respectively, is a rare manifestation of Candida urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Such infections primarily occur in patients with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=see_link\">",
"     \"Emphysematous urinary tract infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ascending infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascending Candida infection of the kidney usually has a subacute to chronic course. Invasion of the renal parenchyma in such patients tends to involve the renal pelvis and medulla with sparing of the cortex. The kidney is usually the only organ involved and the infection tends to be unilateral. Fungus balls and perinephric abscesses can occur.",
"   </p>",
"   <p>",
"    These infections occur almost exclusively in patients with diabetes or anatomic abnormalities of the urinary tract. Among diabetic patients, abnormalities, such as an atonic bladder and glucosuria, promote the chronic presence of fungi in the urinary tract.",
"   </p>",
"   <p>",
"    Predisposing urinary tract abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Renal stones causing obstruction",
"     </li>",
"     <li>",
"      Nephrostomy tubes",
"     </li>",
"     <li>",
"      Prostatic hypertrophy",
"     </li>",
"     <li>",
"      Neurogenic bladder",
"     </li>",
"     <li>",
"      Infected penile prosthesis",
"     </li>",
"     <li>",
"      Chronic bladder catheterization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Flank pain may be present for days to weeks and costovertebral angle tenderness can be elicited in some patients. Fever or other signs of systemic infection are usually absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When only isolated candiduria is found, it can be difficult to distinguish among contamination of the urine sample, colonization of the bladder, local bladder infection, and upper tract disease involving the renal parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urine characteristics, such as the number of yeast or the presence of pyuria, do not distinguish fungal colonization from fungal infection. Although uncommonly found, the identification of fungal casts in urine cytology specimens stained with periodic acid-Schiff or silver stains is diagnostic of kidney involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/16\">",
"     16",
"    </a>",
"    ]. Since the kidneys are seeded from the bladder, blood cultures are generally negative for fungi.",
"   </p>",
"   <p>",
"    Persistent candiduria, especially in diabetics, should prompt radiologic imaging of the kidneys with ultrasound or CT to evaluate for renal involvement. Abdominal computed tomography (CT) scans or sonography may show hydronephrosis, fungus balls, or perinephric abscesses associated with ascending infection.",
"   </p>",
"   <p>",
"    Patients with candiduria who have systemic signs or symptoms should be evaluated for disseminated infection with imaging and blood cultures. Among patients with known disseminated candidiasis, the finding of renal involvement has no specific treatment implications unless renal function deteriorates or flank pain develops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Infectious Diseases Society of America (IDSA) guidelines for the treatment of candidiasis were published in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/17\">",
"     17",
"    </a>",
"    ], and a literature review summarizing the treatment of Candida urinary tract infections was published in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/18\">",
"     18",
"    </a>",
"    ]. These recommendations, along with our treatment suggestions, are summarized in the following discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Asymptomatic candiduria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic candiduria rarely requires antifungal therapy unless it occurs in the setting of neutropenia, low birth-weight neonates, or urinary tract manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/17\">",
"     17",
"    </a>",
"    ]. Renal transplantation is no longer an absolute indication for treatment of asymptomatic candiduria, but therapy can be considered on a case-by-case basis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/9\">",
"     9",
"    </a>",
"    ]. Imaging of the urinary system should be considered in patients who have persistent candiduria and who may be at increased risk for formation of fungus balls. This includes diabetics, those who have other urologic abnormalities that may predispose to fungus ball formation, and neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients undergoing urologic procedures who have asymptomatic candiduria, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 to 400 mg [3 to 6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.3 to 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) for several days prior to and following the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among asymptomatic patients without these risk factors, antifungal therapy has not been proven to be of value because rapid recurrence is common, selection of resistant Candida species is possible, and clinical outcomes do not appear to be improved [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/6,19-21\">",
"     6,19-21",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, double-blind trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      to placebo in 316 patients with candiduria and minimal or no symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/19\">",
"       19",
"      </a>",
"      ]. Fluconazole therapy resulted in a significantly higher rate of eradication of the organism (50 versus 29 percent overall), especially for those who received 14 days of therapy and did not have a urinary catheter in place (78 versus 47 percent). However, cultures obtained 14 days after completion of treatment showed no difference between the groups; candiduria was present in 32 percent of those who had received fluconazole and 35 percent of placebo recipients.",
"     </li>",
"     <li>",
"      A rapid recurrence of funguria after antifungal therapy is discontinued (82 percent at 30 days) was also noted in another randomized trial in which oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      was compared to bladder irrigation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective, multicenter observational study cited above evaluated 861 hospitalized patients with funguria, almost all due to Candida species and almost all with asymptomatic funguria [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/6\">",
"       6",
"      </a>",
"      ]. Clinical outcome data were available for 530 patients. Resolution of funguria occurred in 76 percent of patients who received no specific antifungal therapy, 35 percent of patients who were treated with urinary catheter removal alone, and 50 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      bladder wash.",
"      <br/>",
"      <br/>",
"      The overall mortality was 20 percent, but only seven patients (1.3 percent) developed candidemia. Thus, mortality reflected the underlying disease rather than fungal infection. This conclusion is consistent with the findings in a retrospective review of 149 hospitalized patients with asymptomatic funguria in which neither risk reduction nor antifungal therapy affected morbidity and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the lack of efficacy of antifungal therapy for asymptomatic candiduria, attention should be focused upon reducing risk factors for acquisition of candiduria, such as removal of bladder catheters or urologic stents and discontinuation of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. If complete removal of bladder catheters or urologic stents is not possible, placement of new devices or intermittent bladder catheterization may decrease colonization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Symptomatic candiduria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic candiduria should always be treated. Treatment of candiduria should be tailored according to the identified Candida species and according to whether localized or disseminated infection is present. For patients with candiduria with suspected disseminated candidiasis, treatment should be chosen according to the recommendations for systemic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several agents are available for antifungal therapy for localized bladder or kidney infections. The treatment of fungus balls is discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Fungus balls'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cystitis due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -susceptible Candida spp, we recommend fluconazole (200 mg [3",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily). For pyelonephritis due to fluconazole-susceptible Candida, we recommend fluconazole (200 to 400 mg [3 to 6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily) (",
"    <a class=\"graphic graphic_table graphicRef87677 \" href=\"UTD.htm?24/5/24668\">",
"     table 1",
"    </a>",
"    ). Therapy should be continued for 14 days. Most patients will respond to such regimens. However, recurrence of the funguria is common after antifungal therapy is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Dosing of fluconazole should be reduced in patients with renal insufficiency. (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?29/4/29765?source=see_link\">",
"     \"Fluconazole: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    -resistant yeast can be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.3 to 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for cystitis and 0.5 to 0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for pyelonephritis) (",
"    <a class=\"graphic graphic_table graphicRef87677 \" href=\"UTD.htm?24/5/24668\">",
"     table 1",
"    </a>",
"    ). We suggest a one to seven day course for cystitis and a two-week course for pyelonephritis. For pyelonephritis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    may be added to amphotericin B. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Flucytosine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bladder irrigation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    will clear funguria, but the effect is transient and this treatment is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended for cystitis or pyelonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/17,20,22\">",
"     17,20,22",
"    </a>",
"    ]. Lipid formulations of amphotericin B should not be used to treat urinary tract infections because they do not penetrate into the kidney or achieve adequate concentrations in the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Flucytosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with pyelonephritis caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant Candida spp, such as C. glabrata,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in four divided doses, with appropriate dose reduction in patients with renal insufficiency) can be used (",
"    <a class=\"graphic graphic_table graphicRef87677 \" href=\"UTD.htm?24/5/24668\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/17\">",
"     17",
"    </a>",
"    ]. Flucytosine should be continued for seven to ten days for cystitis and for 14 days for pyelonephritis. The development of resistance to flucytosine is common, however, particularly when used as the sole antifungal agent. Flucytosine is sometimes used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate for pyelonephritis caused by fluconazole-resistant Candida spp.",
"   </p>",
"   <p>",
"    Careful laboratory monitoring of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    is necessary, given its potential for hematologic and hepatic toxicity particularly in the setting of renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little clinical experience in treating Candida infections of the kidney or bladder with the echinocandins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , none of which achieve adequate concentrations in the urine for treating infection. However, these drugs perhaps could achieve appropriate levels in patients with invasive infections involving the renal or bladder parenchyma. Their use should only be considered in the absence of alternative therapies.",
"   </p>",
"   <p>",
"    Efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    in patients with invasive fungal infection was suggested in a retrospective review of six patients with significant candiduria who participated in phase II-III clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/23\">",
"     23",
"    </a>",
"    ]. Among three patients with candiduria due to hematogenous renal candidiasis, the candidemia and candiduria were rapidly eradicated. The other three patients had ascending Candida glabrata infection and renal insufficiency; they were successfully treated with caspofungin after failing therapy with other antifungal agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ). However, follow-up on these latter three patients was too short to preclude relapse of infection. Others have reported failure of caspofungin for treating Candida glabrata urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with fungal infections of the kidneys include perinephric abscess and fungus ball formation. Additional complications, such as renal arteritis with aneurysm formation, have been observed in renal transplant recipients who have acquired Candida infections at the time of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Perinephric abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;With fungal perinephric abscesses, drainage is preferred and can often be performed with percutaneous catheters. Large bore catheters and irrigation may be required since the abscess material can be especially thick and tenacious. Patients with multiple loculations or fistulae may require open drainage for complete evacuation.",
"   </p>",
"   <p>",
"    Although some patients have been cured with drainage alone, it is recommended that systemic antifungal drugs should be given to all patients with perinephric abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fungus balls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungus balls (sometimes called fungal bezoars) should be managed with a combination of surgical and medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For Candida fungus balls, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 to 400 mg [3 to 6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally once daily). We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.5 to 0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (100 mg orally per day divided into four doses) as an alternative regimen. Therapy should be continued until a surgical or endoscopic procedure to remove the fungus ball has been accomplished, symptoms have resolved, and urine cultures are negative.",
"   </p>",
"   <p>",
"    For fungus balls caused by other fungal species, we suggest antifungal therapy appropriate for the species isolated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following represents a sequential approach to the surgical management of fungus balls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic therapy with an antifungal agent is imperative during any manipulation of the urinary tract to prevent hematogenous dissemination.",
"     </li>",
"     <li>",
"      The first step is obtaining access to the involved upper tract with either percutaneous nephrostomy tubes or retrograde catheters passed through the ureter.",
"     </li>",
"     <li>",
"      Irrigation of the involved upper tract with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (50",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      of sterile water) via the catheter or nephrostomy tube should be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Debulking by extraction of the fungus ball through the catheters and lavage should be attempted.",
"     </li>",
"     <li>",
"      After debulking, some authorities suggest irrigation via the catheters until urine cultures are negative and there is no radiologic evidence of persistent disease.",
"     </li>",
"     <li>",
"      Balloon dilatation of inflammatory strictures may be required to reestablish drainage through the ureters; some infections will need open pyelotomy for debridement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The response may vary with the fungal species. In one study of six patients, two of three fungus balls due to Aspergillus required nephrectomy after the failure of such therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/27\">",
"     27",
"    </a>",
"    ]; by comparison, all three Candida fungus balls resolved with systemic therapy and urological endoscopy procedures. Some infections persist despite these therapies, ultimately requiring nephrectomy for cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     In renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study suggested that organ contamination at the time of renal transplantation can lead to Candida infection of the allograft, although this occurred rarely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/49/15128/abstract/25\">",
"     25",
"    </a>",
"    ]. Among 18 renal transplant recipients who developed graft site candidiasis, 14 had renal arteritis (13 with aneurysm formation). Less frequent findings were urinoma, graft site abscesses, and surgical site infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3391497\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3392370\">",
"    <span class=\"h2\">",
"     Risk factors and clinical presentation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Funguria is common in hospitalized patients, and is generally benign. Invasive infection of the kidney is unusual, and is difficult to treat. The vast majority of fungal infections of the kidney and bladder result from Candida albicans and other Candida species. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for candiduria include urinary tract drainage devices, prior antibiotic therapy, diabetes, urinary tract pathology, and malignancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with candiduria are asymptomatic, and the yeasts merely represent colonization. However, it is difficult to differentiate between colonization and bladder infection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Infection versus colonization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical characteristics of fungal kidney infections depend on whether the disease is secondary to hematogenous spread or from ascending infection of the bladder. When present, symptoms and signs referable to renal infection include flank",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdominal pain, costovertebral angle tenderness, and abdominal tenderness. Papillary necrosis can occur and the sloughed papillae may serve as a nidus for fungus ball formation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical characteristics'",
"      </a>",
"      above.) Fungus balls and perinephric abscesses can occur. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ascending infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3392362\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When only isolated candiduria is found, it can be difficult to distinguish among colonization, local bladder infection, and upper tract disease involving the renal parenchyma. Urine characteristics, such as the number of yeast or the presence of pyuria, do not distinguish fungal colonization from fungal infection. Although uncommonly found, the identification of fungal casts in urine cytology specimens stained with periodic acid-Schiff or silver stains is diagnostic of kidney involvement. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent candiduria, especially in diabetics should prompt radiologic imaging of the kidneys with ultrasound or computed tomography (CT) to evaluate for renal involvement. Abdominal CT scans or sonography may show hydronephrosis, fungus balls, or perinephric abscesses associated with ascending infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with candiduria who have systemic signs or symptoms should be evaluated for disseminated infection with imaging and blood cultures. Among patients with known disseminated candidiasis, the finding of renal involvement has no specific treatment implications unless renal function deteriorates or flank pain develops. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3392349\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic candiduria rarely requires antifungal therapy, unless it occurs in the setting of neutropenia, low birth-weight neonates, or urinary tract manipulation. Imaging of the urinary system should be considered in patients who have persistent candiduria and who may be at increased risk of formation of fungus balls, such as diabetics, those who have other urologic abnormalities that may predispose to fungus ball or abscess formation, and neonates. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Asymptomatic candiduria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing urologic procedures who have asymptomatic candiduria, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 to 400 mg [3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      orally daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (0.3 to 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily) for several days prior to and following the procedure. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Asymptomatic candiduria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic candiduria should always be treated. Treatment of candiduria should be tailored according to the Candida species and according to whether ascending or disseminated infection is present. For patients with candiduria with suspected disseminated candidiasis, treatment should be chosen according to the recommendations for systemic infection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Symptomatic candiduria'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For cystitis due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -susceptible Candida spp, we recommend fluconazole (200 mg [3",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      orally daily). For pyelonephritis due to fluconazole-susceptible Candida, we recommend fluconazole (200 to 400 mg [3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      orally daily) (",
"      <a class=\"graphic graphic_table graphicRef87677 \" href=\"UTD.htm?24/5/24668\">",
"       table 1",
"      </a>",
"      ). Therapy should be continued for 14 days. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Fluconazole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      -resistant yeast can be treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (0.3 to 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for cystitis and 0.5 to 0.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for pyelonephritis) (",
"      <a class=\"graphic graphic_table graphicRef87677 \" href=\"UTD.htm?24/5/24668\">",
"       table 1",
"      </a>",
"      ). We suggest a one to seven day course for cystitis and a two-week course for pyelonephritis. For pyelonephritis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      may be added to amphotericin B. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Amphotericin B'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bladder irrigation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      will clear funguria, but the effect is transient and this treatment is NOT recommended for cystitis or pyelonephritis. Lipid formulations of amphotericin B should NOT be used to treat urinary tract infections because they do not penetrate into the kidney or achieve adequate concentrations in the urine. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Amphotericin B'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is little clinical experience in treating Candida infections of the kidney or bladder with the echinocandins,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      , none of which achieve adequate concentrations in the urine for treating infection. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Other agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fungus balls should be managed with a combination of surgical and medical therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Fungus balls'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/1\">",
"      Fisher JF, Kavanagh K, Sobel JD, et al. Candida urinary tract infection: pathogenesis. Clin Infect Dis 2011; 52 Suppl 6:S437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/2\">",
"      Barnes JL, Osgood RW, Lee JC, et al. Host-parasite interactions in the pathogenesis of experimental renal candidiasis. Lab Invest 1983; 49:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/3\">",
"      Ryley JF, Ryley NG. Candida albicans--do mycelia matter? J Med Vet Mycol 1990; 28:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/4\">",
"      Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida urinary tract infections--epidemiology. Clin Infect Dis 2011; 52 Suppl 6:S433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/5\">",
"      Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/6\">",
"      Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/7\">",
"      Ang BS, Telenti A, King B, et al. Candidemia from a urinary tract source: microbiological aspects and clinical significance. Clin Infect Dis 1993; 17:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/8\">",
"      LEHNER T. SYSTEMIC CANDIDIASIS AND RENAL INVOLVEMENT. Lancet 1964; 1:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/9\">",
"      Safdar N, Slattery WR, Knasinski V, et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis 2005; 40:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/10\">",
"      Hitchcock RJ, Pallett A, Hall MA, Malone PS. Urinary tract candidiasis in neonates and infants. Br J Urol 1995; 76:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/11\">",
"      Pappu LD, Purohit DM, Bradford BF, et al. Primary renal candidiasis in two preterm neonates. Report of cases and review of literature on renal candidiasis in infancy. Am J Dis Child 1984; 138:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/12\">",
"      Baetz-Greenwalt B, Debaz B, Kumar ML. Bladder fungus ball: a reversible cause of neonatal obstructive uropathy. Pediatrics 1988; 81:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/13\">",
"      Johnson JR, Ireton RC, Lipsky BA. Emphysematous pyelonephritis caused by Candida albicans. J Urol 1986; 136:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/14\">",
"      Hildebrand TS, Nibbe L, Frei U, Schindler R. Bilateral emphysematous pyelonephritis caused by Candida infection. Am J Kidney Dis 1999; 33:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/15\">",
"      Kauffman CA, Fisher JF, Sobel JD, Newman CA. Candida urinary tract infections--diagnosis. Clin Infect Dis 2011; 52 Suppl 6:S452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/16\">",
"      Argyle C, Schumann GB, Genack L, Gregory M. Identification of fungal casts in a patient with renal candidiasis. Hum Pathol 1984; 15:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/17\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/18\">",
"      Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections--treatment. Clin Infect Dis 2011; 52 Suppl 6:S457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/19\">",
"      Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/20\">",
"      Jacobs LG, Skidmore EA, Freeman K, et al. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin Infect Dis 1996; 22:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/21\">",
"      Simpson C, Blitz S, Shafran SD. The effect of current management on morbidity and mortality in hospitalised adults with funguria. J Infect 2004; 49:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/22\">",
"      Drew RH, Arthur RR, Perfect JR. Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis 2005; 40:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/23\">",
"      Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007; 44:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/24\">",
"      Malani, AN. Failure of caspofungin for treatment of Candida glabrata candiduria: Case report and review of the literature. Infect Dis Clin Pract 2010; 18:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/25\">",
"      Albano L, Bretagne S, Mamzer-Bruneel MF, et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis 2009; 48:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/26\">",
"      High KP, Quagliarello VJ. Yeast perinephric abscess: report of a case and review. Clin Infect Dis 1992; 15:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/49/15128/abstract/27\">",
"      Irby PB, Stoller ML, McAninch JW. Fungal bezoars of the upper urinary tract. J Urol 1990; 143:447.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2415 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15128=[""].join("\n");
var outline_f14_49_15128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3391497\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INFECTION VERSUS COLONIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Candidemia-associated infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ascending infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Asymptomatic candiduria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Symptomatic candiduria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Flucytosine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fungus balls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      In renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3391497\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3392370\">",
"      Risk factors and clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3392362\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3392349\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2415\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2415|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/49/38672\" title=\"picture 1\">",
"      Disseminated candidiasis kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2415|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/5/24668\" title=\"table 1\">",
"      Treatment of Candida UTIs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=related_link\">",
"      Emphysematous urinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/4/29765?source=related_link\">",
"      Fluconazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=related_link\">",
"      Fungal peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_49_15129="Horizontal forehead rhytides at rest and contraction";
var content_f14_49_15129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50165%7EDERM%2F75187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50165%7EDERM%2F75187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Horizontal forehead rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Horizontal wrinkles are present on the forehead. This patient has wrinkles that are visible at rest (top). The wrinkles are exacerbated during brow elevation (bottom).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin injection sites for horizontal forehead rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 417px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGhAfYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDcpaKWvKOkKKKKAEopaSgBaO1JRmgANJkUhNJ1oAXrSUGmlqQAxqLOc4px5pCMCgZGzGq8smOpqHUb6O2QknmuO1TxE2WEfT1pavYdjb1XUVhRgGGa4jVdUlkYhWwvqKzNQ1hpWO59x9BWNc3MknJJA9zWkafVg2XLiWVwSDgfWquxiv8ArVBqkb3C4y34CoXvEycgfjmtlFk3RdIkTP78Ee/FIs5P3lSTHcYzWf8AbiBwAB9M0JdMSSpXPpiq5WF0X3uB0MaD6qKhLoTxEh+nFRrcs3cr7kcUpaQnJ8tvcCkAyeUfwQ7fpk1AZWxg4I96tBQxy0ZX3U0jIDkBv++hzVJhYrr5fUpg+oNDGNmOYwV7Z61OIX28IrD2NNWMbsMCn4Zp3DlIPsiPlom2H0PSlCTIAr546MORU32dzkoCQO4qdS4XBAJ/WjmC1ikJCpwVx6+hq1a4WaORFDAHkGntHHITklD7ilSBh8oJD9V9DQBXeJ4ZG2cgHB70jgja8JIPcHpV1nxIMqI2HOcdaPLSbO0YPdfelcdiEsssanHJPPqKaFwuT26MKneDEYwoDD9frQiq6dMGkDQ1Nz9sH19ajkXMb7cgg5+lWOVUqQCc53ValgWTc8QOCACD64ovYdiksf8Aopxk7mGfwqu+ZGJAJA/lV6ZHitkjycH5mAqtJsWIevpQJqxGqqjZc5Y/wjrUu5U5wB7Dn9ajS2mc5VcA9M8VKLIru81zkddozj8aYiOW8dRhfl9hTrR2DFpm/M00iGJRthLE93PP5ChbsqxMUKZ9dtAjf0q9kRx5CuxHdRXdaH4klt9i3ZCr33NzXlQubyQ/ebn0OP0q7bq5A8xhn0JrKUExo9/sdZhvIgYiCPcir0YllIOEx2Gc14jYarcWm0RyjH1rr9H8ZtBhbmUN7Vk00B6EqXKyAqqgd1Y1NmbJUbQO+T+gqlpmrw6nAGjkRfXnmtUmN1QDGOmKFZiYse/GBjjtinHzMfd5+lAQ7VI54/Gno46HrTEQiV14ZPxzUglHfinvgLmq4USnBGf5CgCxuHv+VGQehBpuwp9w8elKCG4ZcGgB1FG3+6SKTkdRn6UCCijIzzxS4oAQ0YpaMUAJRS0UAZQpaKUVJYlFFFABig0maSgANJ3oNJmkAtFNJ4oLUwFP1pvGKQtmmM2BSGLxiqOo3qW0LFmA4qHUdSS3QksMivPfEOtm4LIHIHtQtdENIi8SeId8rKhyK5K61F3c55z2JxS3IWZiVfJ/2jiqj2kzDOEx7MK3jFJCbbA3fGMKPpVWSdWP3jj602SKZc/ISB6Gq5Rj1Q/lWiSJJJZFP3Vz+NQ58xSHU596RbSRuVU/yqdbK4UgkNjtkVeiDUhMODkA/hSbXUjBNXPsEx2lkYZ7hh/SpBbOvHJ7ck0mxpFJHkwRuZSfyp6faByCTz6VoRWZZgTEzH0Aq5FbqrZ8oBO4Zxmp5kPlZnxRzsocqQvr2qcDYBwj/QVems5JFUqhVexByP50xLRwfunjrmk2UkVU2yPiQKnPUjgVeSKOMZk2SRHgMvP86WSxBAKI5J6gVPb2eMA/KPR6V0Uotle8htiEMKrG+OcEjcf5VUaNZPlO4ED0rpRo4YEAhsddpBFQy6S0ZGc7Ox9KnmKULmKdOkdVcuGzwKYbeRfkI59OxNdAtpIigBQf93rUv2FgC3DL70c4/ZmDLaM1su5TuHXI6U2G2dSFGMnjJrf+zbFLktn+VVWtSpBjyQeRRz3DkM2JG8zYwGCOGPeoooxGWTbtO7IbrW+bMmLleM9u1QpaDzdrDGeKOYTgZBt/Nk+U8Nzz2NWIF/eAEYXoeauXNo8UgdceWfSpY4PM42kNx260XDlMy6tdyswI25xkVXa3ixHhBlevvWxNAwBQKG5zwP61UmtXRFDAgHoM01ITjczZ2VpctnjsKRbeedCIwyp+X61pPDDbxkscuR0C1ULBjhElX9c1VyWisbNYTmR1z3wc002+5sRyR/nWnDbryrKGB7kVLJaFIxsgUDHOMgmldE2MtbUoPluE3Y5y2KBYzk5Clx6q4NTvbDnKbf1pscKZx831Y/0ouFiJUlT5TEwHvkYqVGCNlVJYd89Km/enhJxgdADimu0w+Z5Ijj1ApNhYmttVu7RgYpZEx2611ej+O7hMJckMB/FyDXHqUdDuKA+qnmmIsJU4csfQ/LUOKY7Hvmi+Jba9hUpMg46McGt1ZkmGUO5vavmq2u5beT93Iq+gBrt9A8W3YVYpZFBHAJNQ00Q4nr6bi2Jjx2HarJGMEVyen6zPcABiDx1ByK3LS7ckLIBg9DQmJo0RyKCoIxSJTqZI1c8g9adSN1BpaAEIBGKbt9Min0UwEA9aKWigBKKMUUgMmlzRSE1JYpNNzSUUALn8qQGkNJmkMdSGkzQTQIQnFMPJpS2M5qleX0VuCWYDHrQMtMwUc1i6zq8drG2Dziud17xfDCGWFgzdODXA6jrV3qUuAQFJ7GmouQzW1zXZJmfY2c9hXLyyTSNlyee3eplV3IAYf8B/xqwixxJy3zeg/wAa0Vo7Ds2Uo7Zn/gcD1JxTzZRgjdL+CkmrLHIyEJH5VEVdj0AUU+ZspRHLHbouApf/AHmqJp4YmOIhn6VIEXOGIz7c1JBErNjaPxHWhICBLrf/AKqED/gNSqZCMsM46AE1eNuuzG4Z9AMfpSx2DumY0dQOcsdtPQLFYXDbciGQjuOcU0XEjAgWyAepXNaiWLrjdh8exOKtwWD5Jbp/dxU8yRSiYJlkcgNFEB7JV22sZ5owVgG0c7mGBW9BYonzhFz6kZp8luskg3HJHcUnNFqD6GOtlLjEj5XphBxUqWqKQY4/m/2+a2YrZu3T3qT7IpPzDdUOZagYwjllb53Zz0xVuOyj2gsjo3uK0liKjAVce4pyrISBwB9OlLnKVMorbJt6DPqKUW3GNxwfetGO2KvvDYPrikdCgOGXPbipci1TKaQ/P8zAgdDjBpGjeRSoPyrzirTgmMIF/eNxUxj2Jj+L1qXKxXIZ7WyyLlRjjBFV/JYJ8gXK9q10QHJPWooIAHfPdcjNNTuHIV4YkeIFAQD1B9ajmsi4JUBWPer8C7WZeNoNSmIk57etVz2I5Dm5bZhKyctgZGabBG4l/ulRwG61vzRKi5GN46Zqutskr5Byc/f9PpT5xchmPIwLgIM9yKpyROxJkRsnpu6V0ot1QhXA2/3qme1hK9M+9NSFyHHtZh+Tn8Bmq7xtCT8v0wMV2MlrtT5ESqEsU+TtQD9afMS4HMGd0PDEEf3xkUrFnw0m4nsVbNa1xbMznciFvQLtNZ8tuYnJKvH6c1SZDhcoSxzTNlR09sZqFYnEh3xPx1ArRcuQoDSIfVen5VFJHMQzgs4IwTjmnzIjlsUZjBu+VXQe/NQNI0f3HBX3q2zgDDN09RzUbCBiC+Vz3A4qrk2Km5JXwy7M91/wocMq/u2De+ankt+MIU2npjqagMWw/e2n1Bqk7k2Igxz8yirEbjj5iCPU1FJG2O1RjB+9kGgTOv8ADurT2c6lZi6+hNev+HNSW8s/nGffuK+eYDgjaxz7Guv8LeIp9PuFV2LRk4INZSjbVCaPdbWZchC2T2PrV3rXNafex30CSwn5uuK3LS5WVcA/OOoNSmQ0WDywFOpFGOvWlqhCUGloxxQA00U6koASilNFAGMTSZppNJmsyx/FJmm9qM0AOJ4phPNIzU3OaBis2BTDJgc0NwKyNV1GO3ibJGaQxms6slpEx3AEV5Zr+vTXc7L5xVD0ANS+J9Ya4kKxHcfXsK5RpBG5aRgWraEerAlYGQ9C59zxTQh3/vmCqP4VqLz5JMhBtWpIV3cnLdsmr1GkiykqqmI+FqVZGIHzAD6ZNIsOI/mG0euP5VLEAqYSM49WqbGgqOAQNrH6nFPILHG1ee+M0ohL8qKsQ2x4IwD70aINRkNu5OIxj3q3FCy4yAD7dalht5WXgkD1q9BaMnzNyalyKUSGODI+WMFu5PNWo7ENgykE+gqzFCw2k4+lTpCgUli3r1rKUzWMAjjWIABR+FSHj7q4pqkY+UZFSH7wGKzczRUxAjsPmwAfSkAVOB19cVZABGNv5Uvl5Pbj1FJyLUBsQMmAf1pywk9CF+lPSI8EenapUUrxyQaLj5RCmBg4NKqYx6U1lLNx0zUyITg9vencLWInOPurntmoXwzg46dauOgHQ9O9NRAoLHk1LfQtLqQW0RaUyEH0A9KsyJnt+dSrGYkA9KNpbgcGk+w0ipt+YACoxGfNQH0I/WreNpGOTULRsGUn+8aEFiIAJI3PGBxUkhHl42nmpHQeYB3K0gVxkEjHcj+QoT6CaRXEPmDHPuf8KWKNYiVGNvYVYZ1CgJ06UjAOOh49Kr0FYjZUxxz7GoMuuNi5X09Ktxxh8g43UNAc8UahZFYEScj8vSnsCBjAwe9D2/zc5HuKVhgYYbh600wcStLbBgfX09aptarnBUke4zWqoHXP9aR49wyFPFCkQ4mDcaZGx4XAPvWZdWMkTN97A7iuqMZOQPxFQzRA8EcH1q1IiUTj8bs70WUEfjVW40/c26B9o/uOcV017peULwDDDqBWWNyHEg/E1opNGUoXMOW0kiHKbc9m4B+naq7IxbjIPdX5/L1rqYlfBFuNy94jyD9AapyQ2dwdhzbyA9D90H+YrRTMZQsznnDAZjwp/wBg/wBKgMxHyyIp/DaRW9caRKcvGAxH3mXkfj6fWs1oScxXER47gcirTRDRXBAIIBIPtg1chnXgA5Pp3FVvJkgB2Hch7Hmmu8L4zGVPcg9KLXEz0Twjr8loUR3ynvXrtgUngWeIgsR1FfNFm7B18qTcue56V7B8O9aLstrI2eOhNYyXKyGekRPvX0NPqA5jYMvI71OCGGR0oICilopgJikp1JigBKKWigDBNNNKaYTWZoOBpCaTPFNPNADWNN3YpH4NUb67W3jLMwFIYmp3y28ZJIFeXeJ9dMzuA/yj0p/jHxKGdo43z+NcBLJLdOcknNbU6b3YuZIsz3jStiPAHrTYoc/Mxz/Wn2tqFXJGW9M1biTawIGT2x0FaNpbFJX3FjgZ1+cbV7KKvQqkI6Bj+gqNVbHIyTVqCBpB8q59T2rPfc0WmxHhpX3cc9zV6O0A5k+Y+gqa3gRABgFvU9BV5YQMMeaTklsUo3KcMBbjbhRV2O1AAbGasQRDk4WrVqgeTMjbY1GSaycrmkYkEUapyxwD0461OoAI7n0PSlmYvJnBwentUiDAwcg1DZqojznaM4zR5ZPY+ppY1J5PftmpFU5wOKlu5oohFGFGalCdMDFKmNwBGW9alwQepzUlpBsyM4wfYUCPAOenWrEWGX0NSiND1OT7U2rivYrxxYBzUoHBXH196kEZH3QfrSCJyd2OPakroNyuF+b0PvU6rgcAVMsa5BYDNKyDOVBqlsPcYVDKdq9KjETAouPc1PzkALRtJkYgE9hS31GhiqTnccjtxUixAEnmpEGDycUISzMH6dqkCqRtY8cZqGc/IT6OP6Vdlizu56iqflsVkTk8daNUG+pXlRvPBQ4IBzzVlDmMBgMVI0a71/u7aeYgfu0egdCJYUI+7SfZ8ZYMcelTKCOGHNKxz0zj0qrrqFmUWgcOSM888U9FLLjP1qyRnscUiptbJzSWgyt5fGPm496jMXtV8w5G5aPJ7Ac0JXFoUhFtIOAoPcUsmfw9RVkJgkECmSqMEYwRTRLK5jwQSCO/FQykchhUxLZ6k1DOrMD1P86OawmisxIwUPAPSqt5pqXZ3R5Dt2q5FF5Z+c5J9qlKsq5TH4GqjJ9SXHscuYZLOYiRTtHFPvrSG5USSbgxHyyqMn8fWt6eNZlKyqpPZqzUU2udyh4TwVNWpdUZyjc54C4tZEIc5H3XU9Ku/aIr/C38Cl8Y82P5WPv71cu7RPvRuXhPIJ5K+xqmsAU7Scr2Iq+YycAOlwHKJIHU8gNwfrmsLU9KMDc/gcV0kT5YwzISB0YcMPcH/OaR3bZsk2yIOuR+uKrnaM+XucMUeBvl/Kui0DV3tLuF1OGB60ahYxStui+RuvHOPwrLWJoHxIuB6jp+dVzKSM3E+hvD+ufbrNTKOQOtbUUnzAqcqf0ryP4fasISYbiTIzwCeor1qzeK4hBQgg9xULTQyaLanP1paiwQM55FKsh6GmSSUUAml7UwE+lFHSikBzppppSaQmoNApM4oJwKjY8ZoArXlwsSEk9K8z8b+JQgMMJy3tXTeMNTFtayYPOK8duy95cs78kn8qulFN3YPTYp5kuJSzkszfpV+GFIYx3elVY4ECxjLHqTQnJAHJPU+lbSlfYcYjk3O2B+NaFvFgDA/E96jgiA4Gfc1qQxgKCw6dqzbNkh0NsT978quwIQm3AC+lPtk3KOBjuTVtwOiqAPUVEpFRjdkUUecYxx2qd9vRjn1ot1BGcdKa4Jb72fasmzZJD0VnPyjC4qxGgCqoHSnRjZb8AFmNPjUhcHrUNloCDkVKBhQF+93ojjPHXGepqeNe7Zxnt3qWzRIWGP5OR+NSKgxwOPWrCx5ACjipVQEgEZA9KdhohhiGMgHjpUqxEsfU1bAAHoKIxySB1NNqwXZDGp38dBU4jJyQKeVwRkU5AwbJBxSQ9wVQvUZqQEA/KOKcgB6/hUixr2q9WSVim5ie9KseOKlYkcY56U9SCuBwalWGVyu05OKSIHyxnvzTpojhuT6VYCFRyOnajVj0K+AWzT1j56cVONp+8MGlyB0FHL3GypJGfMU9qhkH7wqBwR/WtF0BxgcCqs8e2ZMADkilJaCRWhjLn5jyox+pqysWBjrTYgFklAHVsj37f0qTsVzS2Ha5Xkj7Dt60wqoGTVwoOMkD60wwAHOcmm0NECRnjBI+podTntxU23np19KcyEjGMUPYCvxgnsKcrBlPtwamSLaAGXOe9DRBeR+VKzJ0KzIC2O1MeMYOeatPEfvDgnrUZRu2D9aLAUzEc8ggVG6LnJFXjnGDjIqB1PJJH0p9AKckasOmRUGwx8q2PY9KvsNg55B5qIKGXcVJzQgsUZGjYdNj9wen4GqzwFlLdfatCSE5G0ADvVZojESVJHt2pktGZjypNhwFbjnvUFzAEYlfu960JY1kBSYAZ6Ecj86ZCi/PFIf3ij5eeG9jVLUykralAbcAFsEcg9xUU8TFvPhKsf4gP51cltwDkdD+lQKrRSHGcdx6iquZSRXaJbmMlAUmXnH9KynwVYkfXjkf41tzAxhmReO9Z1wiBfNTkd8GmiGUbcmGQPC2B7dP8A61es+CNU+12iqHKzJ1B715S6Rn5oy6+wq7o+rtpV2rCRgueoFVuZSie/xTFiCRx3qfhgNorB8NaxFqdqCrDzAM/WugTBwQKadzB6AMr704EEcUtIRg8VQgooHNFAHLk5oBpopGasjUeaqXcnlxsanLcVja5deVbv9KGCR514yunubkxKc5OK5lwkCFf4u5rQ1W42yySucux4FYGXuJCScIOSa3gtLDJBl3J6D1q3CnIwPc1DGNxAA+UdK1LOHexx93qaJMuKJrOLLdPoK14bYABpDx6U22iCZO2rkULbgz9T29KycjVIegGPmGB2FOkO5CASPfFSouRjtSOpZsAcVm2aJWGxghMLkjpzT4ossMjBp0UZzz09KnVCXB9OahmiHSJlsDHy8cVMq7VwACfWmqjbcnAzU0SFgOC3vSuWkOhTIw9WliClR+NLEmCAoqYKXO1AaRQ5FIGBwTSodp5GMGnRW7FsM2cdqnaMDIbp0o1YKw3aHB2k5FBDbuOB3p8KbWzk4PQVKVG8A8D0plbCKQRg1IAzHgYFKqjgoMnoKnjU4ORTXYT0IcMvDUsRHBJ5qV1DAg00RKCB175phdMUEE5H5U043EnPrTn457Umw9fXin5BYRWBx67qmK7ju4xVdYyZU+pP0q4B2xT2E1Z6ELrjBGTSjocip1TPHOKTy8tgmh6hcr/Nk8jn3pHBaPOOhFW2hGMrUS4KuB6VPLZ6jvfUrRoVVCRjsT9akEIDZxz3qwY/kAPQjnFRcsCWOMHBoaBMgaNnfjGKQKwJDDiraJtAI4zTZBnBzUpW1HfUiC4IwtLJnstS43NweKQr8vUA1XQRXGQxLDAxTlBPI6e9K6Ax5PNNi4YqDkH07VOw2hzrnGagdcHoauPjAHT3qvICAACfwoZKIWjDDkcjpUfl88kZqzzjlh0poiwp5yae4FZoxgZwR1qJY8NuXgGrD/IcAZx2xSkgpjGB7UaDKksYZScZqnLGuwg/kauyOqnBbGe1QSRlvcH3ounsKxlGMgkjvxg1WurfaodVPHatgxHPIH0qGVOD1+lCJkjLjKlcMflPr2plwhVMYH1qaWEYJXvSRtnMT8NVXMWiJAssJjwBIOnuPSsm5tvLkIwdp61qTq6MHH3lp7sk0W0j5iOD61SM2rHJzo1tMQASvp7etRyBJk9K2b+3ElsSOJojn8KxJTtOcAeuKtEM3vB2pSWGoIpnKITwc17pps4mt0dmUlgOR0r5sBwd6fw817F8ONaS+sxbyN++QcZ709ncwmjvsUCmI3UfpTwc9DVGQmKKWigDk26U0Uhbk0mayNQlYBTmuE8X6iEDIDx612Goy+XbsTxxXkfiO8aS6lOc4OKcVzMFoc9es9w7O/yx54quDkYHCjoBTpJGc9zU9pbk9R838q6XohxVye0gMm0dzXUWNqETLcIP1rP06DauRjI7+la6EkDsOwrCTubJFmFRjJXp0HvVgrkZx9TTYV2DcakznAJPvWbNEhueAKUIFA/WlUBSec/1pY/mbpzWZokSovy5AqWIYGMZY8U+NAwqaJQrgUi0SCMED361JGgDYGRjpUkCs2SR9KsCPJ6AY9KLdRoS3RcktyKvrCueRj6UyGIgA4AxVqM9c9e1NIbIQuMYHtTnQjBAznrU24AZUVGZCc7RQ9Bq7ZWTh8sTz0qxtLYIIOOlNaPJG7vVmNeAFB2jvSiir9RiKS2fQVWt9Z0uW6+zR6pYvc5x5K3CFs/QHNcz4/u5ZLi20lXK27xme4A48wZwqk/3eGJHfAHTNcy9tA8HkvDGYsY2bRj8qmpVjTdnqe/lnD1bMaLrqaitlpe9vyX3+h62yk5NPEeeMcVy3w9vZrm0u7G5kaV7N1CSMcsY2GVBPcghhn0ArsRkj5R0rZJbo8GvTnQqSpTWsW0/kQNGCuD0pkYypHQCrQ54b06Ux1EYO0Ak9hVeZmn0KyqRIM9MHpU6qSeDx6GkhjO4Fsjg/wA6nQBRnGfakgkxoDYHQ09o8rn8aXoeAPXFKWywJBAzQJXImGYyCMnHSmpHtbnuMYxVlFx7g/rUsi4U45NCj1HzdCp5ZLMew71CV/eZxkd60M8dMcc8U0oCCMc0cgKRWMYxjt2puwb8HoRVnbhMY6UkkYxSaBMrBM5ByMeneo9gLEKCCKmbh8D+dcj8Q72aCytLGCR4jeyMJWRiD5ajJAPbJKj6Zqbrfsb0KU61SNKG8mkvmaEuu6RBdG2m1SwSYHaY2nXIPoRng+1Xn3eYNgX1JryyOCKOEQpGixAY2AcY+ldJ8Pbl4b650rdm3WIT26Ek+WM7WUf7PKkDtk1hGrGq7LQ97NOH6uXUVXc1JbPS1r/N3X3eh2xyQoyPfijaCOO1OMbGTGMgnqDjFSshVdp5HrW1j5xme6shJ27s9/ahN+35MAe9XNqEFeaaVCcADJ7moS1Kb6FIoWGXAz6iq/zI5wBgVfZWXoMj0FRvH6AYPrVWEZ8ii4faQNy0x4inysOAeKtqjLIxKp9aimTc2clV9O1Fh+RUkwBtXmoVA+6Mke/arLx5OA2WNQuAWDEEEUJkNFSSMcjB561RngJYA/eHQ+orUkTeCy9e9RNF8nODT3M5Izd2UG8dOD7VDJGYn4+71FW5Y2jYuoyf4l9RUQxJERn5f4Se3satMzaKsqCRd4xu6MK5i/hMcrcECunJ8ohz64YVV1WJWAdcHIzVRZm0crDIY2wx4PQ+tbvh7UZNNvo54WIweRWTeQqUJTj1Hp71FYymNtkh/wDr1o1dGT7M+k9Ev11PT4p1IDkc4rQU5PPDfzry74ca0YJhaTP8jfdJr1L76+hpJ3OeSsOooQ5HuKKoRx1NLYp54FQscisTUxfE92IrJ/pXj+pyl2bJ4JyTXpfjZylqRnrXmFxhn6ZFa0urGyKBWYhulaVpGWYIvTufWq0Qy3oP51s2UYRdx605MuKL8CBQqYye9aNvCS4LDAqtaR/JuPJJrQQEjisWzaI9gMn2HFJGOx6U1gcgZNSjjvUtlpDGGTzU1unzYFMUZb3q3EnpxUGiRbgjAAHYVZESAgmmxg7RjpVhVBJpjQuOMDj6U9Bz7UAY2g4qQJkAUxolXGD+hpRu3YU5z3FLEBu5FWEVQe3Si1x3sMVDjFSbNqgDrT4wCelPKjjIINHKFxnlZIIPIqePbjGaZkkZ5xT0APXFOOjE79TlPG+iXV8bbUNNTzri3Vo5IMgGSM4Py543Ajj1ya4xRcu/lx6dqLTE4Ef2SQHPuSAB9ScV7Iq/JyM80pUgEgfhSnRhU1kexl+fYrL6bo0bNPur29NUcx4M0efRtOllvgPtt0/myIpyIwAAqA98Acn1JrpIpFKnIwTT9hJ+YYoCgNjiqSa22PJqVHVk5zd23dvzYDB3EfhQu3kt+VO2BX7nPWo5FYyAgDbVa7kC5UuBnHWnIgUEh931qJ4SHDE45qwIty9fwFOzB27kDgMTjr6Cp4FMidMg0v2dMKCfzryDWtVuNfvJpJppP7PDstvbo5VCgJAdgD8xPXnoDj1Jic1TXNI78uwFXMavsaG+93skezBGC5z0pURgMnmvE9N1S88OSi806WXyY/mmtN5McqfxAKeA2OjDv1yK92iEU8EcqSq0ci7kOeqnkGqpTjVXNEnM8tr5ZVVKtbXVNbMqcqTnp7UY3cgZ+lXWhg4zKoBPTrUI8tc81o1Y87mK5AximSg8Lx/jVpmViACPXpTSVGS0fH16Gpa7FJlUxgjkjPaud8a6BPrOnxmz2i+tZPNi3NhX4IZCe2R39QK6sPGRnaAc01iBH8yn1pcqLp1Z05qcNGndHiLwX8UvkzaTqa3A48sWrtz7MoKke4OK7TwToNxp4nv9SiC3dwAiwBsmGMc4JHBYkknHHAFdyrLIoZMY6MD2pmxN3PTI+tYxowhrE9fH59i8wpqlWskuytf11f4WRTdSF4DY9cdKauGPzH8DV7Awec+lV2iAJ25BA5WqcTyEyuyBs5yKUqQpxzjpmnGIgnBzz3pJFUuFyf6VKRRG4GzANV3ODjGTVpkCgjimSKpXaM8+lVYSaKNwq5DA7TSSIShC8tjjinvCyYRef96ja2NpbkdMUrDbKJUjlwPYiqsyZc/N1rRdGUdBgepquyDJYcE+lTYLlSMbMqckUzbj3zVp0+XC1CynqeaNidypPCWG9c5FZk8bQyiRB8rcMO1bYOFIxj1zVeeEMuCOD3qjNmPcKSC8XUDJU96jIiuLRlUlT1AParM6eW3JIx0IqhI7W8244IbnI6GrizOSOcvA6SOjAhh3rNlQq4J6fyrrteijlt1nRRjviucYK4w1bRZg0a+gXgjljbcVdTXvWhXi3thHID8wGDXzzZWjzKRCCZFr074ZaqebSc4YdM1D0ZnNXPSDnORwaKceeaKsxOPk5FVWyoqyfeqN5LtUmsWbnHeOn3QYBrz4gAgZ5rqfGOoAybF5rlIFLtuatafwj6ly1T5xxnFbEKcgf5FULRcEYFaSqVIz+dTJmqRqQEBRjp2q1G2AFHU/pVS0Hy7jVlD+tYtmyQpxuz1pVUswxR9KniGOaT2KQ+NcHoDVuAbjk9agjXnmphuQfKO9JF2L0QAOMc+1TKDkE1Dbnoe571YHOKqwrjg6oN0hAVeSW4xSWeoWd3IUtLu3mdRyscoYj8jXE+JJjqOtXFrMd1nZ7FEX8LyFQxZh3wGXA+tUZbSGQKQgSROUkj+VkPqpHQ1lOvGEuVn0uX8M18bhvrCklfZPr69vxPVI1546VIEy3XisTwnqE2oaLBNc4NwrPFIwGAzIxXd+OM/jW6uOD0rax89JOLaejQ8bl4GDTlDY5J5qJWJl9u9WCeOKaV9SSQKjJjODTY12vg8A0ithxnGKkkBJODgVYeRLnKkelCnd0znPNRRsBwTwanCgfdJBPWmS1YU8kZ4zSxqp9veg4AB6YoWRAdvc9BRbuLpoPdQpzjJo2AHOAac2duB1PFOVRtGD81VYVyrJkg5U9eMVOnAA5weeanijDH5qVgrfeJHbOOlPlFzX0IhHnBA59BXiWr2L+HNQksL/APdQ7ybaZuEljJyAG6bgDgjrxnoRXuo+RRjO09c0rxxujRzQxvH/ABK65H5GoqUo1I8sj0cszSrltb21JX0s0+qPBbK1m164/s3SR500vySSJ8yQKeruegwOg6k17vDZxwWscMQPlxqEUZ7AYotFjjAjhjSGIdFjUKPyFWwAoAIyByRilSoxpxsh5tm1bMqyqVFa2iS6FRbVt2Qfu/ep6oADgD1IqZSFIJBAxjGetJujZjtBGD3NaKKWx5jk3uRBVJ7Djn3qJ1BPzMcdsCpduwll9e5pzIspH07UWugTsVQCMg4b8KUAMMDII7VM6BZcKMD8aa+YyOeDUlX7ECqrZXaR6GnCJdwy3y8ZyORUgI3fKoK9+aYwLPlR+PoKmwXKUwkWT5ASM9c9KYJGaRQSR6jHarrKcY5x35qPCgejfSo5dS+byIcdAcD2qMEs53jAp8nJ2kfKOppTsK7SOPWgZHKwC4A5qtPNHFDJJM6xxoCzsxwFHqTUpKksue/pXnfj64e71yPTpDm0t4VnMfZ3ZmAJHfATj3PtRKSinJ9DqwWDnjK8cPT3l/w7/A6SHxJol1cJDDqVs0jHCDzAA59Aeh/CtbbznGMV5TLGksbRyorxsMFWGQa7HwDeTT6bPbXDvK1pOYVdjklNqsuT3I3Y/CsqVaNW6Ssz1M6yGeWQjU5+aLdtra7932Z0Nwu4YIxnvVVkHl4x09K0ZPm69KqvHgnB/OtWjwEymVAyec1XlPzZGauOuVYZNVWjwPp3qGNECryc0jLlcECnsuH4xzTTwOTweKaIkU5oVdCpALe/esC9iaPKMDs/lXTsdp5AIrOv0BBbqKozZgRMGV4Wbg9uxrBuYvInZG+7/Ktu6tzHJlD8y8jHpVTUIhcQLIo+YcNWkWZSRc8KTJBqCFipGec10l/GLTXIrq0O2N+SB6157Gm2RWjbBXrivS9JtmvNHDn5mA702jFnoekX4ubRGJzx1orm9AMoibyDxjBB9aKVzOxLJwtYGuXSw27sT0Fbl4+xDXnni69PlsgbrWdruxqji9VuDPdsSc85pLVC3OcKOtVGI8w7Tn1NX7MFioUcV0vRWHE0rVMsCa04Y95yar2sQWMuau26/Lk9T2rnkzZItQrgBVFSqOaWJT5JbvRECT061mzVdhwyB71ZhAqMLk1Mi4NItLUnUdKsqo6461Xi5FWVHOOhpobJ4lPrkVMi/L159ahhPA9asINw5AxTA5LxJplzb6g+oW0Lz284HnrGu50ZRgMFHLAjAOORgfhkxSTXTiKxtbi4nPAXymVR/vMRhR9a9I6f0qdBwCRxUSpQnK7PdwXEOMweH+r07W6NrVemv53+7Qp+G9LOlaTBavIJJRl5HAwGdiWYj2yTj2rUVfnHNIhCnPUipAVL8Vt5niOTb1G+XtJYZNTRqeeTuph6g5OO9KzMMbAc0bD3JAm4E55p0TcnJ4pqK3Gc/Slz8xC9OpqXoInRQzZxxjtT9+eFU47moYOW5Pap9ilc85Paqi9CGJ+8dR0XPAoitzuG7kg9T0qQRDoadtBYANitF5hzdh/zZ5X8alG4gds/yqq2Q+CSFHOc96mAdnVmdiMdaaZLRYT5VYsCKApY7uidcGo5fNLj5g1Sbsn5lBPXjoKrmJsObpu4GO2e9PCs33wBk5571XwzynaOp71YQNtw2S2etK9wasSrEqxk/Lub07U9VQgZbgjqKhkJDYU9u9PHKAAcnkg1SIY2df7hLL+VMGRxgE570jMYiQAx46joKfH5pAJ6E5z1xSK6CIpb5g2AeQfT2pigJjkDNSeUwwdwIJPIH86TBzyPl6jigLiupX5jxnNQSqTH8zAZH51JIQD8pIyehpHyY+ccc/Sk10BEKKQikEEAEH6UOxUD2/lTCrkgHaPentwMZ596gt7kTyEruK1ESMA5zn1qQ4YZOR249aaemRx7VO47EcsYYDA/pioGhbHLcdce1WC2Mjt2qPJA5HSk0ildEC9ew9q5DxvoF1d3EWpaaiy3MUflSwkhTLHkkbSeNwJOM8Hca7BiA3zLg0jBWf7pzSbTVmbUa9TD1I1qTtJao8jSz1OZ/Lg0m+Mp4/eR+Wo+rHjH0z+Ndx4a0iTR9K8iR1e5kczTuvQucdPYAAD2FbjqRwufpQACTkYNRCnGHwndmOcYnMeVV2rLolZevXUgOdygE89TiiXGPWplHU96gb5ucGqR5m5UlcjqMUwrmrLQg/e70ySPaOOcUtbhoUZIyCCKjYHPPINWZBz/ADqvJ0OMkUEsiccc1Rm6kY/Crcx4HPNV5QWGR1FNMzkjCv1DZ28OvSsl5NhPGUbhh6Vu3kW47h16fWsWTksrD5x69xVmTM1x5cu5BkZ6V6f8PryK4s3tnHOOK8vvTsl3jOw/oa6DwfqbQXa4bg96toxkeqaCqwz3SdgaKXQ5BLvkAwSOaKEZGHrVx5cTc9q8h8Q3T3N26g8V6R4nuNkLj2ryq8y07fWlSV3c1bsVo1BYInPqa2bGLoFH41QtYioCgfO1dFYQBUAPUdauoy4ItIvygY4FWI12kZ64/KnRRAYLdKa5JnVR3rnZvFFsnEAHrUkQ796ZLjIUdAMVNGOBUstD4h8xz1zUwG5sUxV5BqZQQaCidQM04Dk4qNGO7GasxjIx+dA0yRARg9qnjPA9qi46A1PCuBz1oAsKN2DUyDsf5VGhGBipI2Gev4U0Mk2ntjOelPC/xU0H5c05CR689TTBXEfJwtWNoCDdzimJGM5JqVskc/8A66F3GySMcCjYNo/WnR57jANSIOMA81W5LCJQrDAGBUjIGA7Ec0iZQ47VIxzkZHWqjYht3G5ZWySCD2pSw3cghqQnJ9sdaOoOeD7CrQ7D/LV8gEkDmp4VXaCcA+g9KbF8qHH1JPepY48E5PAGTTsRJkaF2k5GcdcU9jgEfxE5pykQ5IIBPr2qJdxAO7AzwNo5pbDWpZVsOvykn1NSbmBzz6cVXMjqBkKW9ack5J5j7diaq5PKSlclSRjk9aGHHXDE9qYty3IKDtjHanLPkkbeeeM0XTFZgApzu6579qcI8jj/AOvUXmFWyE6dj3oaeTcMoMgdQaE11HZ9BwyqnH1+b+VA3F1AyABTFnlfeCQA3Xil3yAbQ+0EUXQWsNYksQUPFNYNtGBjHXimqzsx+c7v50MzkjBPPXjrUXuirASM4zgEdxUEhJAUn6GpMtyNwbPUEUwnOBtAHb3qZalpWI1GF+c5p5KqB6Uuw4wcHPpTMc85NLbQNxj4J+XtTGYAZPapHAIOO3eoZPu9OelK4JEcjq/TP41HjD5B6jFOdAeBniojkE98VL3L9BjOC556elKc4JPWoyFVt2Mbu9OdsofahbaksVs4HHWom6DFDEjAzTXYkj+dFx2GOBtI5qKRSMDPFTsMLxxVZstgkfhRcCBx8xIPFROu1cHpVhx6VDJwpHNKwmU5VPYA1Wk+6c9far8i5U44JqrIjJgnB/WhESMmcrkj1rG1KIuSyn5wO3cVu3kedxVQD6VjXjCMYbIx09q0RjIwnYyLIh5buPWmaQ5guEdCSmevp9afegxTCZfunriqsBMc5ZeYm6itVqjGR7p4MkWW1Y5BGBRXNeDNQFtbN8xKEfkaKhOxk1qZXiiTJYVwrRF3IHHrXW+JGMkjKD3rnoofLyWGW71NOW5q0JbQiIjAzI36VsWyBAM8ueorOhUoxYcyGtW2jEah5OXPWiTNIotEBQD39KYg/eFqXliCelOQEk1kzZE8Q3HJqwinrUUPWrMZ5Pekih+OM08A5z2pEx3qU4C5NMYsZG6p1bb05NV4hwT2qZSAaQ0ThRvGT+VXYwPrmqkWCRgZq5EMHnrTQyZF9BzUqRgfU9qZEcEk1YQZIOatCbsCoDipAORxkU+NQOcU76Uhpjo0BGaeqAtyKReoA4qVeeh61QrsUrTlOMmkGQeecDmkwX5xj2ouImxn2HQmjbxnsO9R4zxnn0p8anPJO73pgIyk8gYHbNPj6ZPUe1RvvDqu4lAc4qSN2BGEG0nritENp2JlHmc88evU1OqkDk4GKYHwGYoQ2cDngCpMq6gtkZ9arQyZFIAxA6+gpyAhwxwSfXpipHUKM5GPSow2flx1wenNA1sBb5s4z3zTk+Xrg59aaeCQQMA0Y5GTzUlWJVPUknnp6CmkfMCD05wKBtKkkmmFwqk9zTEl2BXEnzHge9LjnBPyniot6gZVSc1KVA2buAB2oKasIgK5UHgj60rHgnGT6GpVALc8semKa5RVORx9aVkiLkeQi8A89aaGIODu21IjF0YIDwOh5/Ko035yc7e2aV9ikBHykNz7+tRBNvJOT1xTpQwPynj0NLgnHIPrUsoQgqSR69KQ4I5+nFDZXrypHFQ3E8cKb2bC9MmlogUW9gZQp2nnNMccgY4qTO9AeCOtLjKZHNKwrlcgEkDv3qCRePerOOoB9vpUcoww4PWkyinImRgCmxr8pDkfWrR4571VcHc1TsPcGQg88g1FMuTgVMwyOvSonbP3uCO9N9gRGTnjvTWUEYzg+lOZMZI69qZnnJpDIHUDjvUDEgAE9asykHp+dVpiQfam9CNyN2YKRnioHCshyx9sVYx8tRldynOKm4mjMcBQQefrWLqiJtJK/jW9eKFHy9PWsG+fK7XGPetIu5i0c5KcNsyCvoaqxxyJN8meO3WrV/CCDg89qqwSOJAN2GHSto7GEjs/DkrpCwUY4oqbwvDLcwOy9e+KKmyIuzN1dsXZJ554rOPyrlsZPQVe1pgt43FZh5lMjnnsKyjsalq2XDBjjParuct6kVlxS72HPSr8Lkjj86bNEWAc4zU8S8fWq6r8wq3EMnpwKzZrEsQrxjrUycHpTIxjFTqB1pIoACxzinkd+tIT6UkhGBjrTAkB4wBU0QJHrVdOe/NXYQMYoGTQL8vvVpPTqahiwOM81OueOOadxlhF2rk8VPHkDINQRkkfNVlBt4Bz9KYiSPpzUoHPNMCgE4HNPT5uKoBVHz455qyiAEYqIKVGe9Tr0yTVJEyYuzrx1pFTDDnrS5IANLweQe1FibsNqp8xp7LkcHFIQDw3enAgEAfSqVh3FCDK8dfWl+Xdk556e1JEGxxz61IY/mAOOeRVIL6ikDA64+tSjO0dcduabGhZs9R2HrUvlg9Tg+h9abJbIHjBJGfypiK+7CtjtzU5P93k00ZDHPX0qbFJsHEhUttBUenpUJZnACoQSfX3qUs+zBGMDPFRqSGB7Umi0tCRVKryv1Bo8osM9acPnPC4wKeN0QI25+tUib9iMRspIP3R1oQls7VA7Y609pnIxtVffFCKxQAuQDzjpRe4X7ipA+BvX5R0zTjbnkBlGe2RS+WpHDFz34pyR4GSPlpcpLZXWEIuQ+fbNKoTJBycjORVh1I4AOT1GagCMBx+tJq2g07kR2gY601dh3Hj6VM6nbkgZ680wR87uPWpHcgkI3H8+tU7u0+0xlX+4eeKusn7wtxilGOlJdmXGbjqivEGRlXsB0qQHI96Qja2SetIzYJLdKBPUCAFIA61XOfut271KWyh5we1RFiWyc0mCGlBt5OKgdOh/WrErA4HrUTLz1zSGiu+FOeeaikwec/hU8w+XkVVcH8aQxScjGcEVDIcHmnuSFzTCQ689aXkAwrx7VCRk81NIMY5IpmD3p9Cb6kJUbvXFRvxnA4NTNkHIpkh6A5qR2M+5X5D6Vi3sIZPlGV7it+4T5Tmsm5yikqKcWZzRyF/CUBweKzVQlsZ5Fb2o7Wct+YrHK7XynT37V0RZzSR6L8P+LSQjnNFUvA1wYROjAjIB+tFTcxZla2g+1MW9a56aQu7HoOgrf8AEL4uHGa58bc/MMCpgtDUsWa8cnitOFjtworKt2LvhRgCtOHjbRI0iXIhggk1eiBPTpVOIZNXYevWsmbIsoBipgOOKhXrgVMOBQXYDgd6YxAHrSsQBzUQOWBpAWoBkmrkQ461UtVJyexrQhTBzQFyWJMDJNTxnP0pi8DnvUinaOnFMaLEI/OrUSHrwcetV4TjBxkn1q4rBeCa0iu4peQo9+DUo+7xxUSY/wD11KuMYPX1qiWSoMgcU4cd6IiDntmlfk8YzVdCLjsKygHtTlUeXzimIuD83epAp6UJBcRhnIHfikUZbGTj+VKwzkdKVSRgECixSZJEGXcSc/WpkO9juPHpUIYdCeDz9aduOPkOCSeQapC3LadC3A9MGoSCSc5wOlPj+VY1IBzUqptwd3B9au11qSnYZsAAXpmjAw2wYPc9+lPZVAAAyx6ZoKBnUHqeTz6UDTISoKksSTj0prRn58AjsPSrIUcBu/IpWIMfbcT2FJopSK8aFlGcdcUDklc57/hUhjIXBP8A9anKCig45PXNK1guQAbmz296niAbjA9aUBg6AgEHPbpUwh3MBj5yB2601G5LZHEjoSVOCe3oKkZQT8y9ealWLa5LqR2KY5z3qRR+6yV46AY/KmloQ5FU9fl6AelNlUhc9KsugUnCjHbnpUL8vhB1PenygmQBRtPamEfIew9alYAEkjjPekbKghemKhllUpuYleTjtUJGfmAJNWpFIw646djUY78j8KhxKTIGwwx0+tMKhhhqsEA8bc1DJuzjbg9qlopeRA4IA46elRFuef5VYBOPujj3qOfG0EjmpGt7ELEEcYJqMgknGM0vqR+IodxnkAY70i7WI2Q7V559+9V5k3D04q3kM2B0NQSIQ5B5FCt0JKki5XGSRUJIXFS3AKqSCfpUJJ2rkUgBmyOaaCcUhPXjilHP0oFYJCSmMdKrvk81ZLe341XY5zikxkMwyOKy7kAAitWTB4HU1m3CnDcZojoRM5PVYwzNjjNYiSMj+VMOD0NbusggnFYKHzXKOeexrojscsjd0S5e2aQKxZccUVHo643h17UVLV2ZMXxC2LuRjk1gRl5GOT9K6LX8faZARmsNeG44FEHoX1LMX7tNqcsf0rUs1wBnrWXb43Vr23TJNTLQ2iXIhg1ci4qpGOAatIRt96xNkWIz81S7ueKghHFSMcDNCLZHIxJqSJct1NRZ+artumWHtTRLZYt4jwwq+hCcHGcVSDEHGQBUkbHf8uST3o9ARaA45OKlSQDPeqZyrDJyxo3nHUBV68ZzTSKuaCTDPzcemOpqwkw+8OAO5rFjuME5B9h3NLJeEDBJXPUZ7VaJbNdbvIwnI9anhu42+63I9a5f7V5ZLxcHqQTUf27KlmUHHUelO9hHYi6C89vWphdJgMpz9K5W3vTIgCP7AMf0p/2lskoDkDle9O4rJnXq6yKGB4qcEHHpiuRtdSIIBJUehrXhvCzAcjI4IpqRPKajnBz0NMLE8ioPOLLyOnB9RTxIrj5TyMdadyloWEYt1zU0I2tUUZBHHrUgbbzngnGaoTdy2hG9SOoqUMcc4qvH6jrTt3r65xVJkEpiLOGwSop5A2D5TnJzio4yeTng1KpHzKx+9z/k1SsGoRopU5ySO2Pyp6xKyjcB8wJ+mKfCqlQWB5wSB2pjMqlSOuMH8adgvcAcEFlJxgA08QiRnYEE8kCnFkZNpb5uzc4HeljkLKAVPQAc8UWE2yRo/u8LnPGf61NHtRSzDBHK4P8AKqrOUZShGAvenzttXC9CAeD096q/UhpskjkPOFOeckdvxqEnCg9AQfwqKaUmNlA+UAcDuahDfPhScdDUOWtilEs5KxZPKkYpjMpwQQPrUM04ChWbgnHFQTP86opwMZ/Ck3bQdiwzAEDHb/JqIuvPp9apPeBjgt8v6mqc+oYO1Mjtg/4Vm5ItRZrBk9s9gKid0BIPGevFYz3jR8Myp3ytV/trcneCPc5pcxSibcsgU5UnHtUTSF+hDYrJbUNy4Kke4zzQlyw5PXsRU3HaxoPKwPPI9fSmO4kX5Tj61Al2kyiN8q/Y9qc0LIxAxg++KTTKUiNiycEAj61EZc55P4ihiyk5UsKjYrk/IevIFTZlcxMCWwwOD3p5IK5yDjtVZ5UVQQCpJ6GjzlYcHB9R3o2E9RrqN5I+7VaVCFyDgVYUnkHpTJCpVgTx/KpaAgLFkCkjIpuCF5xn0pCecEDNMHB68U0IHPHWoUBGaf3Oaa3HSpY0RsMnFU5gdpBq4Wxx3qvMPloRMzkdeU7iQa5YcseoI711euLliSeK5yGLfcDGMk11Q2OOZ03h6B3hLsu7IorsfBFnH9kYSoDgcUUrGTZwXiL5Ll27mudkkMa5Y/Ma6XxIFErs3auRZvMk3H1pU1dFt2ZrWLfKCevetm1bgVg2wxgdBW3bEAL6VFQ2gaaAbc1NF0xmoIjkCp06msTdFmLGMUSEkYpgbC0x3OOKaGyRMdTyc1ahkxnBAzVNRkdcDHerMUJC7yeB70C3LUZ2t6555NPLvNwg4HYDFV4iPUCraSR8KuTnqetUkhjo8Bd0rqPxqlNepECu55D+VWmDOSscZPbLHFQPpUsuWz+HNU1fYRQmvZnUFFSJc45PJqMSMxwZMsO5P9K0l0GRxwqk/wAqeugSYIEa7v8Aa61agyGzNhhYuGMjE565qxPEQWde/U9j9asNpNzCytGNpHUKOKJEnTGTjcMMAOKdrCvcoCcqiruCkdCf8aljuXVxlMMP1+lQSocFWX8PWoGzAqqm/IOcmkUaks++IPEMZHPzd6s2eocgjIx1wf6VjpMXBz17leM/UU3BD5zweQQeRUvUaO7s70XCZ3DzB0PqKV7kBsgjDDn2Ncrp108E+xyM57Hr7itO4nU4ZWBDHH0NF9CkrM6a0naSPB5I7+tXYpSVyRwa52wuvKlGW+R+PpWjBcmOQr1FWpEtGysgzj1qTcCeBms6OckZPc4q3C3rVXItYtoxXlTzjv2oUlmBUDOKhZxjrUkbAAHkntirTGl1LkYJXJxkckdacTwMBME8j0qGI4UHvmnSHJ6ZwATVXsT1Ek+RgAehzk/4UkZIU4GTxz2p0sikAk5bnp2ojb5eSM+tA76E3mBTnFMlYHAUgc9hTMnHI5qrcSYbC5B9amUrEpEiygMRjn3qESHJAOBnFQiUSITxvU81AsgMrMT8ozn61ncuxJPJuv4RnhVLEmq2o6gkO4k5Y9vb3qjdXnledLkb3OF9cViF3ln3OGc9efXt+NQ5dEWo31Zpi8mkVgrCMfedj1AqrNKFJEeQT1ZuT/8AWqDOdyO4VQfncc4PoB3PvUU1zCimOFSp/id+WP0FIr0HNNGpwPNkc9h1NI8jrtEgZT1Ck8/kKggucDEYEZ6lm+8x96s2vl79004DdyODTSIbsWoVMe4urAHqWPNXAyeVuiYKRzzzWdc3EATEBAP94E81VRhkyE7j6EVW2gn3NZhLL8qSRvIDwFbmmrcyJmObjB6ZzVSG4mdwIVQ56knkfjVuFXYsHBAPYL/WkwRON4IkXO3HVTupFkBf97tGe4FWIkjCjNtz64qF41ZsRrjnrQxp9wdMoSuxh6ZqPy4pFyB5Z9jik8gqSWLn6DApJY2jXiTPfaaTLTG7VwR3FMOFHHSo93ykkg+2ahckHKsAP5VmUOkYbu3sahGS3PSkWRmXrx7imbwH64FIhkhU1Hjn1p5YcgZ571E3y4PWkxxCb5RkVWuM7MjvU5bzBg9ahn+5gULUU9jkNcZvmHUisSzcNIM4zmtnWmDSspO0+9YUQMN2voTmuqKujim7M9Z8FyGCB1kOcgGitnwrZxXmlxSYAbbjIopWZjc8q8SpvlfJ4rlZNkZ3E11fidSrtz1rh7osHJbn2opao1ehpWdxvfAH0rdtjlRmuZ08bWBbg+ldLZncAKmqjama8RyoqZOR71Xj4AFWUGTmuc3QszYUYpCTgUjYLYJ6UdTjmgGSRyEcBeamVS3V2HNXPC/h7XvEfmv4f0a4v4ImKPcBkii3Dqod2AYjuFzjvipNUtNR0W/TT9e024067ZS6JMFKyKDyUdSVbHGcHIyMgZrVUpW5mtCFUi3ypkUUCZ6M3HSrkUDFgNgQe3JpsId8eUmF9T3rThVSAMsH96pRRoSW1qijkZPvV5IsRgRkfSoo4cnJOfrV6CMAcitCJaCRw8ZYflVhYScbjlacg/Opk7etWmYvUja3Hpn0qnNYIxO4demO9aY3Y4xT8L6++apyJ2OYudHUg/Jx61kXWjtzldw7ZrvhGCOg96imtkZMED8KmyZSm0eWz6bJE2VBH0pI7dsYyPoeK7+801CvcGsS40/GQRj8KhxNFO5zRRg4yuR3q9GRsyW3xvwfUVPNbMoxx/hVZYSrlW6Vm1Yu9zSU7ogScEYB+uetXreY+d85xkEVQt4wICnUdvaplKqytjBzkj+dJ6DRuoxdBzzV+Fv3SAGstOkZRuM5q1DIWKjoDnNNsVrmhu3YHbtVm3b68VUSReAcVagAPIHBqosHsWkOcbTjPrWfqmq21lcw25eSW8cbo7a2ieaZx6iNAWI98VbyoxuJBrtPgzpdtB4KsdaCI+pa5CmoXVx1Zt67kjz/AHUUhAOgwe5JPRTj7Tcwq1fZJWPO9O1a1vL57ZnlhvUG9rW6he3m2+uyRVbHvjFaZIY8ZXsM+tdz8XNHt9R8EaleMFTUNKgkv7K5x80MkaluD/dYLtYdwTXAWzmaCN8HDANj60qkPZ7BSquqnfdDnEiDdknHbqKjd8pu25xzVnK89AfrVWSRF3cgZ7VizQy559txuj+652kVJOreXtGQOenUmo7uDMTOmTzmluGb7Pw3UYz3qI3Ro7dDGki865kVmztxux/Koy25jHajMgHzuei/SpwjJHIsYGWPNZ10JFXyrc8nqQO9PYL9iO/njjxBCcnHJU5P+ArOGX/dqD9FGSfqa1LfTyo+dsuepqcWqLwBx7cZoUW9wuZkds4AWKP94ep3ZxTDbTHKKSx7k/8A1q3oIUUbdp5/Wr0VsNoyoA9BxVqC6iuY2naS8g/ej5PQHrWzDo8K4IiUH1zV2EIMDB+tXoYk3csfzzWiUdiJXM+HTIt4ZlU47AYFWlsovct2Har5CBdgyMc4xg0g24GG+opuKJuyoLcdCMn9KhlilwdpUZ9K0sjk9frUTsX4Cis7DT1Mo2szcibA+lRmA5/gb/gNabhFB3ciqzsCo2Rkj36VFi7mRNbku3yx89hWffGG2haS6kSCNeS7sFUfUmtu4jX+JtnsprqPg54XsdXvNQ8QarCl0bS6NpYRSgMsOxQXlx03lmIz2CjGMnNQpc7sTVrezjc8ptdR0+6m8u2vLadwN22ORWOPXHp71bwp4x+NfSnjHwnpPi7SnsdXtlc4/c3CACa3fs8b9VI/XocgkV8z2PneTsutrXMMj28rKMBnjcoxA7AlSaVeh7PVPQijX9ro1qPJIIUDilZABnuakZFJBGfwpp7+grA6EyB8KxJODVaUko3rU90cEcVWlPyk9u9T1CS0ON10eZOw6EGqcIV5Y45BlweDWjrYCyMc9aqaTGWuoyOcGuiOxxzPavB5MOlRqR2HSipNARv7OiLDtRTRzM8c8Xvtkb1riHfL4x0rsPHMb/bG29MVyOM9RVUlaJrLcnslLS5NdTpy8rmuWhba6joK6jTz+7BqKpvSNFsh8CrSE7c1XHIB9akV+MGuZnS0SDBqvqzyR6ZePBnzUhdkx/eCnFWUGRU0anuvB9apbkM+wPC1hYaX4b0yx0cJ/Z8FvGkBQcMm0Yb3J6k985riv2gLW1m+HU1xcBPtFrd20lq5+8JDMiED6q7KfYmvLfAvxE8QeEtNj0yG3tdY0uH5beK5naCSBeyCQK+5B2BXIHGcYxD4p8T634zvLaTWjbW1lav5kFhaksgkwR5ju2C7AEgcADPTPNem68HE8+GHnzozrVlzjDCtSIIw5XJqjCBnkjNadvtK9cVxo9GTsTRKABtqwjc4I596rxkAnmgyKgLMelUiGXgc55FK0qpyxrDn1dB8sPzH17VTmu5JV+Zj9BSc+w1Sb3Ok+3Rq2C4/OmtqkIzg5A7gVzcSluQAB71KAyITS5m9S/ZRR0KanGw+XP5UjanF3z6cisMGQx5UqPqcULLJu2tGc/SncPYo2vt8MvHmD2qOVVdSRg1ktHE6Z5EgPfpiojI8TAxuxX0NVaSJ9muhantwynK4OfWs2aDDHHNW4b0S8Pw3+1xUsihxn1qea5Li4mQN0eRyKmhlEh2vjPrUlxGQM9RVNvlO6k0VGRtRuVi2nnH3fWrtnufJJwRxgVi202cdq17STaox0rMvoacQLNn8MVchOCetUoG6Vbjbnn8KaEywq72yR06ZNWvB/ia/8G276ZLps+qaGrs9q1q6efahiSYirlQ6Ak7SGyBxg4BqrndwDxTyCefatYVHB3RnUpKorSLPjHxVf+MNOfSLTTLjS9Hn+W8mvGTzp4+8SIjMArdGZiDjIA53CIDam4A9OaZGNvX9KcWJztpzqOerFClGmrRK8xJOScA+lVZ4yuGRjweavOAV2kVVmOBisWjRMp3GEUlWOT1561XeXCc4z7U66bB9OapyNlvQVS1BjHYsDgVGsYHQAfhT5G6BTimZ5yD+dXsTqxxGMkdqovNIs4G35RU010saHcwAqg9w8x+QbfQmpd5aI0jG25rw3IDDO2rQvrfOC68eprmzGSpZnycZx6U9YyT8vI+laJMr2aep08WoWwxtkXd9anW7SRs7lx71y/lvEquAMN2q9Ep2gbCTjoDRZicEtTpIJo8nLH65zU0cgxkNknua5E+akoHTj1qVLy6jPEhIHQmi7JlTv1OrYhlxx+FNI+tc/DrLr8sqhsdxVyDUYpXAViD6NQ2ZuEkaBGexx3qOVcjG7aKUShsf0qOQKTls07EJlaTy1yB82fxq74I8WP4K1K+S7tLi40K/kE7G3TfJazbQrNs6sjBVyFyQQTg7uIHwBwKrOQSQRUxk4O6KlBVFZnc+JPjBpg0+SLwnBdalqjriIz2ktvBCT/FI0iqSB/dUE9uOo8jtIPstpHCZvOdQS8jDBkcnLMcdyST+Na8qoCfU9hVSSNey49zU1asqmjClRjS1RBvGDxz0qGQHPAwKsYGfpUUgyKxNOpVl5xnmq0yfIauuvpzUEgyp+lTYt7HD68u2Y5ORUOikfa4scDPWrPiRcM2RWZo/N3Fg4weQa3jrE4qm5794fYNYR9wBRUPhgN/ZyHI6UVa2OZnk3jeMb8gV5877SSeg6V3/AIquUuMqHBx71wV0MyYUVNF3N5DbXc8gIHJrsNMXEAB5NctaDYw7k11mmLhBSrbGtFGjCMgelSOuMUxSQPapQMkGudHSySL5l44qzEhJGelRxKNx4qzEpDe1Va5BZhUjpV6FA2DUEZCqDg/hVmM5Psa0SsCZYtlAJxirkeBxnFVIcdqdNKIwWJAAFaLQlu5YubqO2hLyNxXO3N+925XO1D0ArNvr9725IRj5YOAKlt1wRn8zUN3NYxUd9y6jFeB19KnZwFDE4+tZ1zeRxnC5Le1Y99d3BXcN23OOaL30RTdtWdH/AGsluw3AMucHBp7eIYURiAVz0z1rjJpG8rJlJbPbiua1rUjG4jRzu7mqUJ7GLrQPVovE9vLb+URGCCT9amt9ejyVdVC9trZrw2K9cMcMxbtzW1oWoGV/LnwW6e9aeyktbkqvDsewxajbXLFFGAehY4xVs2zKishDL6156se1Q9vK4x15zXU2L3y28UgzLGRk49KfLJboqNaMtEy/PbkqVKkEmoklkt2CN8yevcVZTUVmX5zhz1BqZYkmAMZXODnNS0pbGl+5VeXIwelULkYyDV6W1ZCVwxXtntVOeNl+R+h+6az1W5FuxFbS4bBOcVv2bg45rlJCYpOvWtrTp/lU5zUNWZa2OmgPy471cQntyazbSTOCK0oiMdOam9hlyLOMgDilaUr94c0kRAAJzUnG09MmqvoJb6j1YMuStM3BW6U1doxnNDbT24+tANDZpDk/L2qjO3y85qy7csCPxrPuXwDSvcSKd3LjIrOabc2OtLdybnwDUWAE3Ywa0WmoMe8m0ZJqhcXEm0ndgHgDFXfILDLZxVd4Mkkj5fTFDRcEUirEq7ct1ANSxbkUAcsanKBR84APpVaa5WMt5a7iB0pppGlkTomAd7gE8HPSo/7Rt7ZCGYbh6Go2sbq5tZJpmaNVGVGMVy4gRWJYs7dyTWvJN+Rz1MTCOm5vS+JreANgqaavjFDLEsckWSckH6V5r4rvDG6RJ8qn0qnoNhqeryNHpVvcXUwUkpCpdgByTgdqFSk3uZSxUbbHrA8XLKwH7ggfxd61LXWbO6GCdrnuOleIaZcmO+WNyTk4IJrqIFfJ+zFg/UYpezmtgVeD30PTGjjZN0bjnqKibcRk5WuQsdYuY22S/MVOa6O11OG7UI7HJ6ZNZc2tmdMZXNS01GaLBLbk71sW9/5y9ciubmh2qNh+X27VCsklvIsikjHX3qk+UUoxkdlvHc01z6VTs7lZoldSDkVYMgIIx1q7pmDViJhz3qtLnk7ask4qOU8ZrKSLTKEi7V46nrUB9O1W3ALZJqGRQGqLDRXb7p9agIznnip26nHSq83yDgnNZss47xSCrkryfSsbSlVryIk8E81veK1barjoK5i3kAkBU4Oa3hqjjqLU958P3Ea2EYQEYFFcT4d1kx2YQycgdzRRdnO0kea3NwZSWZ/wrMebedqDA9aklxgkmoVXHTGTWsYpI1ktSxZqWlUDpXZ6cuIxXLacuXHr611tkNqCsKzN6SL6oNtIn36ki6fWmkYesDoLUY6cVaVScEVWjIwPWrUPJyO3arRLLlt/d7irgx+NUoFw+7oat9frWsdjN7liMKFzmsTxDclYCinrxWqzBUJJrm9Uk8yb5RlacnZDhuVNPjMY3E+9Ou7tidkZxTJJRGgUHr2qtzHOGkIB7CoV5adDVmna2REayzHLHmofEREcERThc4rQs51njXDDjtS6rYm8smTbzjjFdsIpLQ4ajlJ6nDyM/lNuU7q43X98d3vYcNXeRoZA8EoAkXg5HaszVLCO4hZZBkdAa0W9zlu9jF8BeJrXw54kt9T1HTIdUihBxbzfcJxgE/TrTtLuG1HXJrqGJYo3dn8tOi5OcCqy+H4/M5dsZxjNdVpGlpaqvlRnHqDVOzJStqbkUiLDHGMZx831r0bwxbsdHhEiAkrXB6daLe3yJEmBwW9q9PtLm3srdUZ1wox1pXVi4RlujL1TRkMTOnyyg8Y71jw2upwIbhbeVoY2wzgcD6ntXRXWtwc7UJ96t2viqyfw7f6ffGRAQDbiHADP6v69q5pqm9bnbTlVitroyLbUIrzbHLiORe3c0mp2bG2bGB3X1Ncfc+UNReWC+UbTlWb5f0rrdHvvt9ipJG/GMisedp2Z0zp2V0c5OhZD/eHWpNNk5HT6VoX9p5buRzWPbNsmIHXNZyCKOw0+Q45rUgdt/Nc9p8pOPetmB2XHGQeuazbKsa0bsIwcfjTlYuCQD+IqGOQMnFTx8Lx0q1qK9gZ+m7+VK5wOhxTH9TgVHI5x94YApNg9RJHAXgdqyb5yEJzxVq5lZsEHPasrUXz1NCYKJSQmSQ4qeJTJcLGPujkmoLVvmPBNadnau0uRlRWvMO3Un+z/AGmQLGAI14BrJ1e+t7IiIMGkJwK19av002zVUzgnDEcGuLu5rCVnbzH3nDDIyfzolK+xVKF9ehIBPcSgFsA8k+1dBpVpBGVCDJ9TyaEuNJGiGKxS4F45H7yZRgYPY9sgnj6VUt7u4t+GRSvqK1jyQ2MainUN2/gMtnIv+ya8zliZWkQnaR8vNeiQatEybZlZTXJeJraDzTcW53Z6gda6FNNaM4KlKfY8t8ZWEznzUGdmcgVleE/F2r+E7qe40a6e1nljMLOo52nqK77UvK+UHDlxkr6Vzz6XDK7SeSMZ64zVJq1jCUWzC0SGS6vVnfcFznJHU13EKyBAUGM8ZPpVS3tBBbnK7WP3RjrWtbhpI44EBMzAD6VSYavY1/DFmt7cTM65UALz60/VtHe0Yz2+eOcCui0O1g0uwVJHG88k55zTNR1GLYyKu/Pesqig1ZnVSVRO6MPS9V3BVkySOCK1rhFmi3J09q426iuIblpoEYIeorf0O+82Ly3ODjp6VwqXK7M9Bx6mppEnl5jboK3VPygjGKwbUfv+h471tRDI7gVcX1M5oWRcjdnpTC2Uxx7VY2Aqck1UlUpk9qHpqSuxG+cggcCo5iTzSmU8+nvUW/JPpWbaNLELKRnHU81Ulzk5q5IeSc1XChsg1DKOc8SIDAARmuP8ko+5QcV3muR74GAHOK44EqxQ9fStYPQ5qiuyOOeSLlGxmipjbdziiqujPlMR4wQOKrsh6AcmtRYcxg9KgEYD8VSkVKJPp0RRlB6966m0Q4Ga57T1JlFdLa9OtYVWa01YtICMcU9l5BoTmpByDiskbISHk+9adnHnmqdsoDdOta9vH8nHFaRJkSInGeKXGDntSrleMimyNg9q0vYysyrdSNghR+dYV2HLereg7VtShmJ54qtNbrHGTjn+dTLzNYqxgpHuk3PkkdMetXIYFm5ZanW1Plbh39aW3RlUdQaI6FLViraopG1sE1bj8+EZV8j3ptvbPy7E4zViS3lkZTjjsK1TfQLJ6MxtS05rmTzQVjk/vL3qm2izOuDIm0f7NdG9vJnKjgDGT3p8FpKQTtLc5Ge/tVc0rkSpQetjlh4YlllDtKB7KK1RofKl2cAAADOAa6WzVnLDysgHg+lXGt5ZrQwsFPYY61p7zW5mqcE9jBstMWByE3Iep961BZ/JnOanjs5I1VWJBI6/yqfyykS5J8xT361PIuprzdjMlthkYBZehOKrPpiGQbgcnt6Vtxq2wAoN2cg1OsaecGOfy61MoIaqNHPRaDbuxDxqR7itS004Wm3ysBB0ArViWHlmyHPvxUNw6kFU69ahwuRKpJ6FG92+S5bGcVySf8fLH0NdDqchSHb61zyHLmsWraFQN7T2Awc10Fq4deQa5mxcAA9q27O6QNtPHpU3S3NGmzVRlDYBIx2qws8YU/NgjvWeZFxgDmlA3HAwfb1oTtohct1qX2eJlGHBJ96rPIqpgkZqKQryBxiqcrbywDfkaU2VGFxfMG84aqN824Ng9KdjnJOMVWmkALZopvuVJE2kIJGXPrXRoBGMjI9a5bTJ/LYY7munL7osjgY5rVRctjCbsyjqFstwMyDI96zF0uIP8saj8K3QBt6gY9agmAjO75hxVxgOM3sZjW8aKcDnoB6VBJC8rBIiNuT82PStSXZKqKw/I80Jbhj8zBUHAA71pZMalbczHt1CKGbJOOSOKheBX3/IMKoJJ6fh61svbM6EEbec1JDbqrRsAHYHADHjHvRyIHUOZXSIbjPmRJzyMioW0GBYZRHCoiIBfb39K6u2s2jeZ1QM754I4FPtLDy7AphtzEhk6KR1q1DQzlJdTi20O1jIRo9xPrzinrpsNlICYgmRkFRXUtaFGwAo25Hrmql9ZNLHlT8x4NKUbdRwaXQomBPKViSQe4NR+SqAhgD6GtAWxWHaeOlLJZEqD6c4oUS3PzMbYHVgwGB0FZzWZinMkKlQeoFb/wBm4cY60/7MMBTzWM1dAnZkNjuGGkXkdfetq1ZGA6fSqhtyqikQkMAOlTHQUlzI0nHJIJ5qCVdyHIpUlPGcEVI0gPbrVtozSaMqUYPTmoHHPFXniO454HrVWeA4+X86wbNkVpCdnHaolyTk1Y2cEYpjKNue9TcpmZqK74mx6Vx13ExlJHBBrtbkZU1hXFsSxyKuDOeotTLhyV+YHNFbdtZfLuUcGiq5kZ8jZxSszfIKckYILH8KRBhiasIOAT0q72G1cs2CfOPWtpPldQOlZ1gnOSK015IOOlYzdzSCLqYzU8a5FV4xyKsw5z7Vma2LMER4OeavxsV43c1VQhQKlBz0qkFrkjlguR1qJd8j88CrMa/LzT0UDgdatIlpDY4QDzUV1FuwKvpHtHJzTJV3ADP4+lUQ9zNWIDjHFPWAHJ/yanZCCcg4HelAJIPTFAJj4oiyrxwO1Wlg5GaYjcYUcVaiJBA7VpEGxgg3sDgVbFv8uOASKchXd71Ork8Efia0uQ22Jb2ojjYAkE9eKmijVHPUt605ASmD2PJp2Spyo/WqUiQlhJUmQccVTmjXgRgEn1qeSRixyeg9KjLLIwBPHrUvUpaFYjdIfmAx2NNUYDB22E46U64Kw4XAfd0OeaYAzlehI9aSTvYq+hFcfvVA5LdOKjeXy4cn5n6U93KqMcNWVfXAiGMbiO+arRak76FHU7nfIRzwKpRjAFB/eF2bvzT1znpXJKV2bwiXLRivfpWhYxs8m44A9ao20ecAVrwArjauR7Vg1c3XkXkOQBzUiowbK5IFVwxBGSB9KllZgRgEjFWn1JsSb9w6YqvIAFYqecfSp13MmRkEe9VpGO8kj8qUtFcpIpsSqtuNVnHmRsauXaq6jnBquq7UbnNKKsOWqKqyCCQHtXR6fP50W0csRXPTqpjyByOtSWNw0Ug2nKnpXXSlrqctSNzpZkRWQLwcZz6mo5v3hJ53dAf60kGJGzuzkdPSlVwzfdCY6+tbtGaZWAyMds/exVmON/lPYnikiXapJ5HYUiMXZRuKgnH0FRbuaN3LSsCOc/Wp7dUAJTk1UCmOXB5XPpVyJgBu5xVIykSs/PAzn2pVRWAJA/rT4wGHDfWnMEAII59RVXMyu0WWJfg5yOKqzREkjjHWrxVjlgc/WoH3A8Dj2obGii0HYimSL8oA+lW3RzzggVGyMDyOKzuX6lFoRnP51GgAJJ7VeMXvUXljBBHFTIpMaMFRxxUUkYySBU2xlTA5z0zT3GAAeDWZaM8Eoe9P34HPT1p7gN06VG/CYpWLtcRZN/BNMlJBNRgg5NBYGM5PNZ36FctitK3zccVXbO05qZm4YAZx3qEk7QTxUjZWkAJwDVeSAB81a6SkY47VO8IK57VSMJrUqxxLtzGceoooZGUkpxRU3NopWPOkUMcYqwq8Co4cE4qwv3xWrZEoq5ds1wvFXIc9DVS16+maux8HHeoZMdy3HgYNWoXG7riqiZxg8VLFwaks0VxilRjmolPy9amhHBY0LcqJbgBxkmp0A39arwk4yKtQqX6nFUmKRaQDbycUxkHUDIp6+hqYBdtXczsVAvUYP402WHaue4q7gDBxTZl3oRinfQl7lSEjHFTpKM7TSW9sV4zxVmOyJOS2Pwpq4OyFiI69asrJjGKaLdVwN4yKd5Pu+PatNiL3H+YF68etAuOTwTSso2gbR+NOjhK8lvwFNPXQWhBPKRH8qnPvTJC+F4HzDFaaW6tgAbt3GPU1WlhZZCMcI20d8mraYKSM4R7pPnBIHAFOKbkZQSrDG0jvV4mNWZWI8xRkH/Gsq+lBPyErgYyO9TZRQ7uRXu5THHguSccmueuWZzjP4VfuWLEDt1qkiku5HNYVKlzaMbDVAI6U5U20vIbBHJpyIQxJrBO5skWrbhgc9ua2LUELuGCKx4W3Hb3robRMRrtwKErsb2IhCxJYCpw2cAc/SnyHgqTj6UJH/c5Iq0uUV77ixKcHv9aJYwUJA5p24hcDg00s3lEHBNDa2DUy5/mBBxuB4qusZY47dKfdth+R8wp67ggcfjWS1Zq1oUpNwcd+1N+44Cj3FW2AcZ7GmSRb0weCO9XGVjKSuOt7yQAhSM+57Vbgn3l3wecdaySPLlII3duK0LUBQCRkfWumFRvcxcUjSEhAw2c1Ygj81fu7SKrRuXAYdemfSrMMhGOeetbaXMmyxPEI2VM5HXdipI4/MyA44/2sU5ZCzbuuQae0O1RJjk9eMimZ3Y5EKDGwHHUhqcGYDd9361E4QHOWzj0xUikpHxux1OaVxWGF8DKqcChWVjkYzURllBOYwVIznpTTtc7tpU1nzovlZNIvfOarvnBwc09Q3Zt3pTU5bOzB6c0pTGoldgQBuyKcFXb8p5q2Y1PcVVmG3t1pXsPcgOcEHrTWVpMe1TbQQCKQdSB37VLNIopzAoCMVVkYlSV5rQmQnORVKcbVJWs2bKxSY5HHB7ilA+XJpkrAtyMGlU5Qc9KjqWyOV8NntVcvuJ44qaYcZ9KrE5U02Z3FGGfirzrhRgZ4rOhBLnNbAX5R64prYyfxIzpF5yBRVto8GiszdHlkIwcVKxCtxSRrhuaHIyDitXuFVWZesj861fI2yE1kQSjzFAPfNa4BkAaho5+pKjEnmp4iOKrnIHFS2/OakpF/cNuangcuuDxmqKjPfirdryQB1qTRF+A8+wq9EDjiqkBHJP3f51bjO5MjhfSqTG1cmXPTr9aVclsZpByuOgp0eR9KdyWiaMbjjFEi475pUcDhPzqPcSx70XJ5SQMRjAqUOT/FUbbQOTzTRwRjp61XMxOKL8QVRyMmnlxkE4X09TVdCQuV/M0xFy+WJyOc1pzdjPlvuXQQzbVIz70yFj5+2QEpTWZSCy+nJokl2REtncRnPerUiXEnaTa/yHA6A+nrVOWdtuVJOOASaqNKX3BtyjgVG7HbtBIFQ6rexapWEedhlcnJ68VWucj73Tr0qwzAn5OcVSkkZiRjI6VDkaKJTnHz5B4xTIkx2/8Ar1PgM209jTeje3asW7s0SIWQl+R3pJG6jt61O43ruXtVZz8pPekiibT8CUFvWuhhcbQO1c7ZDe4Gelb1mDkk9MfnTTGx9xwQwPSpYJDjIB6UFlbGB1qWEbVIx09Ke7ug6WZA5dnFL84JNWShLg44xUUg2Ak5x2pNW1C/Qx7xWEuVUkZ61Mu3y9p6kVJO2InZRk1VBaQB8Yx2qU7aop6oWFQFw3TNSIP3hBxjFLGcqTTlzg84PtQnYl6kNxED90Uy2IbhuMcVPnfn5Tkd6jRBvGRjnqKanZk8umpLCzK5Gfzq7FI5jKttB9RVVRk+vbirCj5cdDXRCZlKJaifKbS5x6VY+0SI6qMsPQ9Kz4pGzhsA9OKuQt5hKBgO2TVc/Ylw7mn58cqDcMN3HrTRtZtrFgR61QLyJIDkYPBx3q8rgKCvYdDWindamThbYa8e0c9u46Ui84OQP9k1CzP5uARj2qyuXxuA47jtWaaL5bIr/wAbE5HtSkfKSOnanyyFRhhmlc5UbcEGpHYgQEg4J3CmM2SA2CakIDDluR3FVplO8AnBx19aL2Q7XY9lAXg5qFztBX9aCrR55zTSwYbgMjuKls0iiPeS2GNVrgbQSO9WZAACR17VVl3H7w4qWzVLqjPnHIOKaowDuqS5PytgdKh3b4+etR1E9hk7AKc1AF46jFPddwxyT70wKQpB6VRmwt1YzDGcVvQx54NZdgNzDnpW3CpwMVpFGW8iF7fmitOOHcvNFPkuPnPFbiPy5CKqyjn2rZ1q3Mcm4DisablTj0rPqdlRX1GW0mXJ7it2yctCOa5eByjsCeprpNLO6Ig1b2OSasXV+6TT4hjJ96jU447Gnr1wKyYky4BwMVcgGw7u9U4ecFulXIgM8ZNSzaJchOBzyPSr0OAvqfSsuJsSc9BVqOT5iM8ChM05S+CefSnbiR6CoYWJ5P61KDgFmOSelNsViSLO0Y6VJ9OBUGTsG04qZAcc9aSehLQ/APA7dTUixgEf3aRF4PI9zUq4VRxkmriQxGJVSAPmx1qOJyy4I6du1SsM+vNR/Kg4HNaXZNgM7rxximvIzZ39uSKhMhbJPQUxieMc5qeexXILK6jG4H1qHcXyVwMCpJVycdTS7dqqoGKh3bKtZFdFMYYc4prrkqAKtiL5ST3NIyjPA/GmkJ7mfLHjGMCoRH84LcAVpOoPaoJom27h26j1qXHUaZVYhF45zVFsmQj04q3ckrj9aqKc8kc0DLthHtB4wa27TlTWJAxMgX+Gt612qgwKaRTBI2LFQOB3q1HGUjwDzUkKjYduOacoZTzjFEYWG5XGbSTjIqK5GeO3TNTZBJKjkVDcKSNw60PVCW5SlXBI7GqsR2Eqf1qzcShWGfxqBnDDdx7VKtcHsTLtGFAAzUkqEcL2FR24DMpPT0q+yA1Vroi9mUhGVjJ5qNFDDI9a0VjyrZ5FQxxKGzj8Knl2GpEKoA45wam8ssCc8VFOh3/SrMRygAFUuwNaEG1kbgcGlhLnO77pqeTgjigZAIwPpTYuhKkoMYJwMfrViI7uTjPrWZJmNxj7pqxDINgwapVOhLgaDsAR0BPFKsn8PH17VQaRt6lsgeoqVnRQM5P0p8+ouQfM3JJOMdqapIFGA3upoOY255FJPW5dtLCbgzZHBHUU1hvOeODxTyyA8EfWodygnOdvr6U2xcoSN8wVuM96jbEbjaaRjuBPcU1j8o3c+ntUXuWlYa5DZ2/iKqzvwBjkVK5IUnpj0qszhgC3HtSky7FeckDJHWqgU8EdDV6f5l4H4Gq+3A9KRDehEOp45qJxv4HHrUjAjJqPBZiV6VaOdsu6cmCT6Vv2qjaKy7GPEGa0rZwoxWi0JhqzagiTywT3oqt5p2DaaK0uhOLPJvEP3K5pvufnRRWEtzvl8BlN/wAfA+tdRpv3KKKroc1XYvL9406P/Wt9KKKyM0XIv9WtXYOn4UUVDOiBJH981YTtRRUG3Utx/dFTSfcX6UUVbIW46LrVv+FqKKCWSp90fhTx90/SiitIbkDD0H0qGf8Ahooq5giBejU5Ov4UUViuhbH9xSSfe/GiitOhL2A/6uox1oopdQGL99qdN9xvpRRTjsJ7mPddDVQdKKKhD6l61/1w+lb1v9w/SiiqiUi/B0NSyf6sUUU3sD3IF601u340UUIpmNe9T9ahT7p+tFFc8fiZUtkW7PoPrWpH/H9KKK2jsYvcbD3/ABqOHqfrRRUvoHcSXqaRPv8A4miiqW5XQkfoKc39KKKfckgl/hqS36Giis+pfQmk6D8KbP8AcH1oorR7MUeg+P7g+pqT/lkaKKIDZXl++aib/UGiijoUtkPHT8Khk6miik9hIik+631qrJ2oookWhrffNV5P60UVMTCYxvuUyL/VUUVrE55bmzZ/6gVMn3looqp7FUNzQH+rFFFFIctz/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The five injection sites in the mid-forehead (red) represent the sites for the injection of botulinum toxin into the frontalis muscle for horizonal forehead rhytides. Treatment of the brow depressors is also required, and is represented by the injection sites in the procerus and lateral obicularis oculi muscles (white).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15129=[""].join("\n");
var outline_f14_49_15129=null;
var title_f14_49_15130="Fluoxetine: Drug information";
var content_f14_49_15130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluoxetine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/58/30630?source=see_link\">",
"    see \"Fluoxetine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"    see \"Fluoxetine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      PROzac&reg;;",
"     </li>",
"     <li>",
"      PROzac&reg; Weekly&trade;;",
"     </li>",
"     <li>",
"      Sarafem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Fluoxetine&reg;;",
"     </li>",
"     <li>",
"      Ava-Fluoxetine;",
"     </li>",
"     <li>",
"      CO Fluoxetine;",
"     </li>",
"     <li>",
"      Dom-Fluoxetine;",
"     </li>",
"     <li>",
"      Fluoxetine Capsules BP;",
"     </li>",
"     <li>",
"      FXT 40;",
"     </li>",
"     <li>",
"      Gen-Fluoxetine;",
"     </li>",
"     <li>",
"      JAMP-Fluoxetine;",
"     </li>",
"     <li>",
"      Mint-Fluoxetine;",
"     </li>",
"     <li>",
"      Mylan-Fluoxetine;",
"     </li>",
"     <li>",
"      Novo-Fluoxetine;",
"     </li>",
"     <li>",
"      Nu-Fluoxetine;",
"     </li>",
"     <li>",
"      PHL-Fluoxetine;",
"     </li>",
"     <li>",
"      PMS-Fluoxetine;",
"     </li>",
"     <li>",
"      PRO-Fluoxetine;",
"     </li>",
"     <li>",
"      Prozac&reg;;",
"     </li>",
"     <li>",
"      Q-Fluoxetine;",
"     </li>",
"     <li>",
"      ratio-Fluoxetine;",
"     </li>",
"     <li>",
"      Riva-Fluoxetine;",
"     </li>",
"     <li>",
"      Sandoz-Fluoxetine;",
"     </li>",
"     <li>",
"      Teva-Fluoxetine;",
"     </li>",
"     <li>",
"      ZYM-Fluoxetine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F172763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Selective Serotonin Reuptake Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F172719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, bulimia:",
"     </b>",
"     Oral: 20 mg/day in the morning; may increase after several weeks by 20 mg/day increments; maximum: 80 mg/day; doses &gt;20 mg may be given once daily or divided twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Lower doses of 5-10 mg/day have been used for initial treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bulimia nervosa:",
"     </b>",
"     Oral: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Initial: 20 mg/day; may increase after several weeks if inadequate response (maximum: 80 mg/day). Patients maintained on Prozac&reg; 20 mg/day may be changed to Prozac&reg; Weekly&trade; 90 mg/week, starting dose 7 days after the last 20 mg/day dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Depression associated with bipolar disorder (in combination with olanzapine):",
"     </b>",
"     Oral: Initial: 20 mg in the evening; adjust as tolerated to usual range of 20-50 mg/day. See",
"     <b>",
"      \"Note\"",
"     </b>",
"     below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Fibromyalgia (unlabeled use):",
"     </b>",
"     Oral: Range: 20-80 mg/day (Arnold, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Obsessive-compulsive disorder:",
"     </b>",
"     Oral: Initial: 20 mg/day; may increase after several weeks if inadequate response; recommended range: 20-60 mg/day (maximum: 80 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Panic disorder:",
"     </b>",
"     Oral: Initial: 10 mg/day; after 1 week, increase to 20 mg/day; may increase after several weeks; doses &gt;60 mg/day have not been evaluated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Post-traumatic stress disorder (PTSD) (unlabeled use):",
"     </b>",
"     Oral: 20-40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Premenstrual dysphoric disorder (Sarafem&reg;):",
"     </b>",
"     Oral: 20 mg/day continuously,",
"     <b>",
"      or",
"     </b>",
"     20 mg/day starting 14 days prior to menstruation and through first full day of menses (repeat with each cycle)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Raynaud&rsquo;s phenomena (unlabeled use):",
"     </b>",
"     Oral: 20 mg/day (Coleiro, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Social anxiety disorder (unlabeled use):",
"     </b>",
"     Oral: Target dose: 40 mg/day; range 30-60 mg/day (Davidson, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment-resistant depression (in combination with olanzapine):",
"     </b>",
"     Oral: Initial: 20 mg in the evening; adjust as tolerated to usual range of 20-50 mg/day. See",
"     <b>",
"      \"Note.\"",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When using individual components of fluoxetine with olanzapine rather than fixed dose combination product (Symbyax&reg;), approximate dosage correspondence is as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Olanzapine 2.5 mg + fluoxetine 20 mg = Symbyax&reg; 3/25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Olanzapine 5 mg + fluoxetine 20 mg = Symbyax&reg; 6/25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Olanzapine 12.5 mg + fluoxetine 20 mg = Symbyax&reg; 12/25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Olanzapine 5 mg + fluoxetine 50 mg = Symbyax&reg; 6/50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Olanzapine 12.5 mg + fluoxetine 50 mg = Symbyax&reg; 12/50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Upon discontinuation of fluoxetine therapy, gradually taper dose. If intolerable symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of fluoxetine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 5 weeks to elapse between discontinuing fluoxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate fluoxetine in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving fluoxetine and potential benefits outweigh potential risks, discontinue fluoxetine promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 5 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume fluoxetine 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F172738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"      see \"Fluoxetine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: 8-18 years: 10-20 mg/day; lower-weight children can be started at 10 mg/day, may increase to 20 mg/day after 1 week if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Obsessive-compulsive disorder:",
"     </b>",
"     Oral: 7-17 years: Initial: 10 mg/day; may increase after 2 weeks if inadequate clinical response to 20 mg/day; further increases may be considered after several weeks to recommended range of 20-30 mg/day (lower weight children) or 20-60 mg/day (adolescents and higher weight children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Selective mutism (unlabeled use):",
"     </b>",
"     Oral: 5-18 years: Initial: 5-10 mg/day; titrate upwards as needed (usual maximum dose: 60 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Upon discontinuation of fluoxetine therapy, gradually taper dose. If intolerable symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F172720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Some patients may require an initial dose of 10 mg/day with dosage increases of 10 mg  and 20 mg every several weeks as tolerated; should not be taken at night unless patient experiences sedation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F172721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Single dose studies: Pharmacokinetics of fluoxetine and norfluoxetine were similar among subjects with all levels of impaired renal function, including anephric patients on chronic hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic administration: Additional accumulation of fluoxetine or norfluoxetine may occur in patients with severely impaired renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not removed by hemodialysis; use of lower dose or less frequent dosing is not usually necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F172722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination half-life of fluoxetine is prolonged in patients with hepatic impairment. A lower dose or less frequent dosing of fluoxetine should be used in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cirrhosis patient: Administer a lower dose or less frequent dosing interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Compensated cirrhosis without ascites: Administer 50% of normal dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PROzac&reg;: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, enteric coated pellets, oral: 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PROzac&reg; Weekly&trade;: 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 20 mg/5 mL (5 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg, 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sarafem&reg;: 10 mg, 15 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7873368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Prozac&reg; &amp; Prozac&reg; Weekly&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088999.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088999.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sarafem&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089119.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089119.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7744183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bipolar I disorder and treatment-resistant depression: Take once daily in the evening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Major depressive disorder and obsessive compulsive disorder: Once daily doses should be taken in the morning, or twice daily (morning and noon).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bulimia: Take once daily in the morning.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder (MDD); treatment of binge-eating and vomiting in patients with moderate-to-severe bulimia nervosa; obsessive-compulsive disorder (OCD); premenstrual dysphoric disorder (PMDD); panic disorder with or without agoraphobia; in combination with olanzapine for treatment-resistant or bipolar I depression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F172759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective mutism; treatment of mild dementia-associated agitation in nonpsychotic patients; post-traumatic stress disorder (PTSD); social anxiety disorder;  fibromyalgia; Raynaud&rsquo;s phenomenon; treatment of paraphilia/hypersexuality",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F172774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FLUoxetine may be confused with DULoxetine, famotidine, Feldene&reg;, fluconazole, fluvastatin, fluvoxaMINE, fosinopril, furosemide, PARoxetine, thiothixene",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PROzac&reg; may be confused with Paxil&reg;, Prelone&reg;, PriLOSEC&reg;, Prograf&reg;, Proscar&reg;, ProSom, Provera&reg;",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Sarafem&reg; may be confused with Serophene&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Reneuron [Spain] may be confused with Remeron brand name for mirtazapine [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F172761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages listed for adverse effects as reported in placebo-controlled trials and were generally similar in adults and children; actual frequency may be dependent upon diagnosis and in some cases the range presented may be lower than or equal to placebo for a particular disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (10% to 33%), headache (21%), somnolence (5% to 17%), anxiety (6% to 15%), nervousness (8% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (12% to 29%), diarrhea (8% to 18%), anorexia (4% to 17%), xerostomia (4% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (7% to 21%), tremor (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (3% to 11%), yawn (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (1% to 5%), chest pain, hemorrhage, hypertension, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (9%), abnormal dreams (1% to 5%), abnormal thinking (2%), agitation, amnesia, chills, confusion, emotional lability, sleep disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2% to 6%), pruritus (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Ejaculation abnormal (&le;7%), impotence (&le;7%), menorrhagia (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (6% to 10%), constipation (5%), flatulence (3%), vomiting (3%), thirst (&ge;2%), weight loss (2%), appetite increased, taste perversion, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision abnormal (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (1% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (3% to 10%), diaphoresis (2% to 8%), epistaxis (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acne, acute abdominal syndrome, akathisia, albuminuria, allergies, alopecia, amenorrhea, anaphylactoid reactions, anemia, angina, aphthous stomatitis, aplastic anemia, arrhythmia, arthritis, asthma, ataxia, atrial fibrillation, balance disorder, bone pain, bruising, bruxism, bursitis, cardiac arrest, cataract, cerebrovascular accident, CHF, cholelithiasis, cholestatic jaundice, colitis, dehydration, delusions, depersonalization, dyskinesia, dysphagia, dysuria, ecchymosis, edema, eosinophilic pneumonia, erythema multiforme, erythema nodosum, esophagitis, euphoria, exfoliative dermatitis, extrapyramidal symptoms (rare), gastritis, gastroenteritis, GI ulcer, glossitis, gout, gynecological bleeding, gynecomastia, hallucinations, hepatic failure/necrosis, hepatitis, hiccup, hostility, hypercholesteremia, hyperprolactinemia, hypertonia, hyperventilation, hypoglycemia, hypokalemia, hyponatremia (possibly in association with SIADH), hypotension, hypothyroidism, immune-related hemolytic anemia, kidney failure, laryngospasm, laryngeal edema, leg cramps, liver function test abnormalities, lupus-like syndrome, malaise, melena, migraine, misuse/abuse, MI, mydriasis, myoclonus, neuroleptic malignant syndrome (NMS), optic neuritis, orthostatic hypotension, pancreatitis, pancytopenia, paranoid reaction, petechia, photosensitivity reaction, priapism, pulmonary embolism, pulmonary fibrosis, pulmonary hypertension, purpuric rash, QT prolongation, serotonin syndrome, Stevens-Johnson syndrome, suicidal ideation, syncope, tachycardia, thrombocytopenia, thrombocytopenic purpura, toxic epidermal necrolysis, vasculitis, ventricular tachycardia (including torsade de pointes), violent behavior",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F172694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluoxetine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently, within 5 weeks of discontinuing fluoxetine, or within 2 weeks of discontinuing the MAO inhibitor); initiation of fluoxetine in a patient receiving linezolid or intravenous methylene blue; use with pimozide or thioridazine (",
"     <b>",
"      Note:",
"     </b>",
"     Thioridazine should not be initiated until 5 weeks after the discontinuation of fluoxetine)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F172674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Fluoxetine is FDA approved for the treatment of OCD in children &ge;7 years of age and MDD in children &ge;8 years of age.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic events and rash: Fluoxetine use has been associated with occurrences of significant rash and allergic events, including vasculitis, lupus-like syndrome, laryngospasm, anaphylactoid reactions, and pulmonary inflammatory disease. Discontinue if underlying cause of rash cannot be identified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Relatively devoid of these side effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants. Bleeding related to SSRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause insomnia, anxiety, nervousness, or anorexia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight loss: May cause anorexia and/or weight loss. Use caution in patients where weight loss is undesirable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of MI or unstable heart disease; experience in these patients is limited.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glycemic control and may require adjustment of antidiabetic medication; hypoglycemia and hyperglycemia has been observed during and after cessation of therapy, respectively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed in patients with cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Fluoxetine monotherapy is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"     Safety and efficacy in children &lt;8 years of age (major depressive disorder) and &lt;7 years of age (OCD) have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May cause mydriasis; use caution in patients at risk of acute narrow-angle glaucoma or with increased intraocular pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; a lower dosage or less frequent dosing may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a previous seizure disorder or conditions predisposing to seizures such as brain damage or alcoholism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents which lower seizure threshold: Use caution with concurrent therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria). May also cause  agitation, sleep disturbances, and excessive CNS stimulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long half-life: Due to the long half-life of fluoxetine and its metabolites, the effects and interactions noted may persist for prolonged periods following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Upon discontinuation of fluoxetine therapy, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F172756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (major), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2B6 (weak), CYP2C19 (moderate), CYP2C9 (weak), CYP2D6 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: FLUoxetine may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose should be reduced by at least half, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: FLUoxetine may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Galantamine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: FLUoxetine may enhance the QTc-prolonging effect of Haloperidol. FLUoxetine may increase the serum concentration of Haloperidol.  Management: Consider alternatives to this combination when available.  If the combination is used, monitor for evidence of QTc prolongation and increased systemic haloperidol concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: FLUoxetine may enhance the adverse/toxic effect of NIFEdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NiMODipine: FLUoxetine may increase the serum concentration of NiMODipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of FLUoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: FLUoxetine may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: FLUoxetine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of QuiNIDine. Fluvoxamine appears to be the only SSRI of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F172709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, tryptophan, kava kava, gotu kola (may increase CNS depression and/or risk of serotonin syndrome).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F172698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Fluoxetine and its metabolite cross the human placenta. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of fluoxetine or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments of fluoxetine to achieve euthymia. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F172725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F172699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluoxetine and its metabolite are excreted into breast milk and can be detected in the serum of breast-feeding infants. Concentrations in breast milk are variable. In comparison to other SSRIs, fluoxetine concentrations in breast milk are higher and adverse events have been observed in nursing infants. Maternal use of an SSRI during pregnancy may cause delayed milk secretion. Breast-feeding is not recommended by the manufacturer. Long-term effects on development and behavior have not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F172700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F172697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (FLUoxetine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (4): $147.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (PROzac Weekly Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (4): $174.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (FLUoxetine HCl (PMDD) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (28): $172.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (28): $177.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (FLUoxetine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $259.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $266.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $160.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (PROzac Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $822.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $843.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $506.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (FLUoxetine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/5 mL (120 mL): $118.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (FLUoxetine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $78.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $280.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (30): $89.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sarafem Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (7): $70.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (7): $70.93",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F172683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mental status for depression, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; signs/symptoms of serotonin syndrome; akathisia, sleep status; blood glucose (for diabetic patients), baseline liver function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F172687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic levels have not been well established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: Fluoxetine: 100-800 ng/mL (SI: 289-2314 nmol/L); Norfluoxetine: 100-600 ng/mL (SI: 289-1735 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: Fluoxetine plus norfluoxetine: &gt;2000 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F172701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actan (CN);",
"     </li>",
"     <li>",
"      Adepssir (PH);",
"     </li>",
"     <li>",
"      Adofen (ES);",
"     </li>",
"     <li>",
"      Ansi (ID);",
"     </li>",
"     <li>",
"      Ansilan (CO);",
"     </li>",
"     <li>",
"      Antiprestin (ID);",
"     </li>",
"     <li>",
"      Auscap (AU);",
"     </li>",
"     <li>",
"      Biozac (BG);",
"     </li>",
"     <li>",
"      Captaton (AR);",
"     </li>",
"     <li>",
"      Daforin (BR);",
"     </li>",
"     <li>",
"      Dagrilan (GR);",
"     </li>",
"     <li>",
"      Deprexin (BB, BM, BS, BZ, GY, HU, JM, SR, TT);",
"     </li>",
"     <li>",
"      Deprizac (PH);",
"     </li>",
"     <li>",
"      Deproxin (TH);",
"     </li>",
"     <li>",
"      Deproz (ID);",
"     </li>",
"     <li>",
"      Dominium (EC);",
"     </li>",
"     <li>",
"      Elizac (ID);",
"     </li>",
"     <li>",
"      Floxet (HK, HU, UY);",
"     </li>",
"     <li>",
"      Fluctin (DE);",
"     </li>",
"     <li>",
"      Fluctine (AT, CH);",
"     </li>",
"     <li>",
"      Fludac (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Fluketin (SG);",
"     </li>",
"     <li>",
"      Flunil (IN);",
"     </li>",
"     <li>",
"      Fluohexal (AU);",
"     </li>",
"     <li>",
"      Fluovex (MY);",
"     </li>",
"     <li>",
"      Fluox (NZ);",
"     </li>",
"     <li>",
"      Fluox-Puren (DE);",
"     </li>",
"     <li>",
"      Fluoxebell (AU);",
"     </li>",
"     <li>",
"      Fluoxeren (IT);",
"     </li>",
"     <li>",
"      Fluoxone (SG);",
"     </li>",
"     <li>",
"      Fluronin (TW);",
"     </li>",
"     <li>",
"      Flutin (CO, MY);",
"     </li>",
"     <li>",
"      Flutine (TH);",
"     </li>",
"     <li>",
"      Fluxen (TW);",
"     </li>",
"     <li>",
"      Fluxet (DE);",
"     </li>",
"     <li>",
"      Fluxetin (HK);",
"     </li>",
"     <li>",
"      Fluxil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Fontex (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Fropine (KP);",
"     </li>",
"     <li>",
"      Fuloren (KP);",
"     </li>",
"     <li>",
"      Fuxetine (KP);",
"     </li>",
"     <li>",
"      Huma-Fluoxetin (HU);",
"     </li>",
"     <li>",
"      Lanclic (KP);",
"     </li>",
"     <li>",
"      Lorien (ZA);",
"     </li>",
"     <li>",
"      Lovan (AU);",
"     </li>",
"     <li>",
"      Margrilan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Moltoben (DO, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Motivest (PH);",
"     </li>",
"     <li>",
"      Neupax (CR, DO, EC, GT, HN, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Nopres (ID);",
"     </li>",
"     <li>",
"      Nuzak (ZA);",
"     </li>",
"     <li>",
"      Nycoflox (EE);",
"     </li>",
"     <li>",
"      Oxedep (CL);",
"     </li>",
"     <li>",
"      Portal (HR, HU);",
"     </li>",
"     <li>",
"      Praxin (HU);",
"     </li>",
"     <li>",
"      Prazac (KP);",
"     </li>",
"     <li>",
"      Prizma (IL);",
"     </li>",
"     <li>",
"      Prodep (IN);",
"     </li>",
"     <li>",
"      Prozac (AR, AU, BE, BF, BJ, BR, CI, CL, CN, CZ, ES, ET, FR, GB, GH, GM, GN, HK, HR, HU, IE, IL, IT, KE, KP, LR, LU, MA, ML, MR, MU, MW, NE, NG, NL, NZ, PE, PK, PT, PY, RU, SC, SD, SG, SL, SN, TH, TN, TR, TZ, UG, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Prozac 20 (KP, MY, PH, TW);",
"     </li>",
"     <li>",
"      Prozac Dispersible (KP);",
"     </li>",
"     <li>",
"      Prozac Weekly (KP);",
"     </li>",
"     <li>",
"      Qualisac (HK);",
"     </li>",
"     <li>",
"      Salipax (BB, BM, BS, BZ, GY, JM, MY, PL, SR, TT);",
"     </li>",
"     <li>",
"      Seronil (FI);",
"     </li>",
"     <li>",
"      Sinzac (TW);",
"     </li>",
"     <li>",
"      Symbyax (MX);",
"     </li>",
"     <li>",
"      U-Zet (TW);",
"     </li>",
"     <li>",
"      ZAC (ID);",
"     </li>",
"     <li>",
"      Zactin (AU, SG, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F172673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits CNS neuron serotonin reuptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine, or cholinergic receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F172693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Depression: The onset of action is within a week; however, individual response varies greatly and full response may not be seen until 8-12 weeks after initiation of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; delayed 1-2 hours with weekly formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 12-43 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95% to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP2C19 and 2D6, to norfluoxetine (activity equal to fluoxetine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parent drug: 1-3 days (acute), 4-6 days (chronic), 7.6 days (cirrhosis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolite (norfluoxetine): 9.3 days (range: 4-16 days), 12 days (cirrhosis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (10% as norfluoxetine, 2.5% to 5% as fluoxetine)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Weekly formulation results in greater fluctuations between peak and trough concentrations of fluoxetine and norfluoxetine compared to once-daily dosing (24% daily/164% weekly; 17% daily/43% weekly, respectively). Trough concentrations are 76% lower for fluoxetine and 47% lower for norfluoxetine than the concentrations maintained by 20 mg once-daily dosing. Steady-state fluoxetine concentrations are ~50% lower following the once-weekly regimen compared to 20 mg once daily. Average steady-state concentrations of once-daily dosing were highest in children ages 6 to &lt;13 (fluoxetine 171 ng/mL; norfluoxetine 195 ng/mL), followed by adolescents ages 13 to &lt;18 (fluoxetine 86 ng/mL; norfluoxetine 113 ng/mL); concentrations were considered to be within the ranges reported in adults (fluoxetine 91-302 ng/mL; norfluoxetine 72-258 ng/mL).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arnold LM, Hess EV, Hudson JI, et al, &ldquo;A Randomized, Placebo-Controlled, Double-Blind, Flexible-Dose Study of Fluoxetine in the Treatment of Women With Fibromyalgia,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2002, 112(3):191-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/11893345/pubmed\" id=\"11893345\" target=\"_blank\">",
"        11893345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Black B and Uhde TW, &ldquo;Treatment of Elective Mutism With Fluoxetine: A Double Blind, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1994, 33(7):1000-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/7961338/pubmed\" id=\"7961338\" target=\"_blank\">",
"        7961338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bridge JA, Iyengar S, Salary CB, et al, &ldquo;Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-Analysis of Randomized Controlled Trials,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 297(15):1683-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/17440145/pubmed\" id=\"17440145\" target=\"_blank\">",
"        17440145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coleiro B, Marshall SE, Denton CP, et al, &ldquo;Treatment of Raynaud&rsquo;s Phenomenon With the Selective Serotonin Reuptake Inhibitor Fluoxetine,&rdquo;",
"      <i>",
"       Rheumatology",
"      </i>",
"      , 2001, 40(9):1038-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/11561116/pubmed\" id=\"11561116\" target=\"_blank\">",
"        11561116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson JR, Foa EB, Huppert JD, et al, &ldquo;Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placebo in Generalized Social Phobia,&rdquo;",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 2004, 61(10):1005-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/15466674/pubmed\" id=\"15466674\" target=\"_blank\">",
"        15466674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dummit ES 3rd, Klein RG, Tancer NK, et al, &ldquo;Fluoxetine Treatment of Children With Selective Mutism: An Open Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1996, 35(5):615-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/8935208/pubmed\" id=\"8935208\" target=\"_blank\">",
"        8935208",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emslie GJ, Rush AJ, Weinberg WA, et al, &ldquo;A Double-Blind, Randomized, Placebo-Controlled Trial of Fluoxetine in Children and Adolescents With Depression,&rdquo;",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 1997, 54(11):1031-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/9366660/pubmed\" id=\"9366660\" target=\"_blank\">",
"        9366660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gonzalez-Rothi RJ, Zander DS, and Ros PR, &ldquo;Fluoxetine Hydrochloride (Prozac&reg;)-Induced Pulmonary Disease,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1995, 107(6):1763-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/7781383/pubmed\" id=\"7781383\" target=\"_blank\">",
"        7781383",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hetrick S, Merry S, McKenzie J, et al, &ldquo;Selective Serotonin Reuptake Inhibitors (SSRIs) for Depressive Disorders in Children and Adolescents,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2007, 3:CD004851.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/17636776/pubmed\" id=\"17636776\" target=\"_blank\">",
"        17636776",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horton RC and Bonser RS, &ldquo;Interaction Between Cyclosporin and Fluoxetine,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1995, 311(7002):422.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/7640589/pubmed\" id=\"7640589\" target=\"_blank\">",
"        7640589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jackson C, Carson W, Markowitz J, et al, &ldquo;SIADH Associated With Fluoxetine and Sertraline Therapy,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(5):809-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/7726326 /pubmed\" id=\"7726326 \" target=\"_blank\">",
"        7726326",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jennison TA, Brown P, Crossett J, et al, &ldquo;A High-Performance Liquid Chromatographic Method for Quantitating Bupropion in Human Plasma or Serum,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(2):69-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/7769789/pubmed\" id=\"7769789\" target=\"_blank\">",
"        7769789",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kingsbury SJ and Puckett KM, &ldquo;Effects of Fluoxetine on Serum Clozapine Levels,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(3):473-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/7864284/pubmed\" id=\"7864284\" target=\"_blank\">",
"        7864284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kurlan R, Como PG, Deeley C, et al, &ldquo;A Pilot Controlled Study of Fluoxetine for Obsessive-Compulsive Symptoms in Children With Tourette's Syndrome,&rdquo;",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 1993, 16(2):167-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/8477412/pubmed\" id=\"8477412\" target=\"_blank\">",
"        8477412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McKenzie LJ and Risch SC, &ldquo;Fibrocystic Breast Disease Following Treatment With Selective Serotonin Reuptake Inhibitors,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(3):471.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/7864280/pubmed\" id=\"7864280\" target=\"_blank\">",
"        7864280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murthy R, Newton K, and Qureshi J, &ldquo;The Association of Fluoxetine With Seizures,&rdquo;",
"      <i>",
"       J Psychopharmacol (Oxf)",
"      </i>",
"      , 1994, 8(3):187-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reilly JG, Ayis SA, Ferrier IN, et al, &ldquo;QT",
"      <sub>",
"       c",
"      </sub>",
"      -Interval Abnormalities and Psychotropic Drug Therapy in Psychiatric Patients,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 355(9209):1048-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/10744090/pubmed\" id=\"10744090\" target=\"_blank\">",
"        10744090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MA, Hardin MT, King R, et al, &ldquo;Fluoxetine Treatment of Children and Adolescents With Tourette's and Obsessive-Compulsive Disorders: Preliminary Clinical Experience,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1990, 29(1):45-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/2295577/pubmed\" id=\"2295577\" target=\"_blank\">",
"        2295577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MA, Scahill L, King RA, et al, &ldquo;Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents With Obsessive-Compulsive Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1992, 31(6):1062-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/1429406/pubmed\" id=\"1429406\" target=\"_blank\">",
"        1429406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sternbach H, &ldquo;Fluoxetine-Clomipramine Interaction,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1995, 56(4):171-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/7713858/pubmed\" id=\"7713858\" target=\"_blank\">",
"        7713858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1290-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/18628446/pubmed\" id=\"18628446\" target=\"_blank\">",
"        18628446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2010, 11(4):604-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/20459370/pubmed\" id=\"20459370\" target=\"_blank\">",
"        20459370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsapakis EM, Soldani F, Tondo L, et al, &ldquo;Efficacy of Antidepressants in Juvenile Depression: Meta-Analysis,\"",
"      <i>",
"       Br J Psychiatry",
"      </i>",
"      , 2008, 193(1):10-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/18700212/pubmed\" id=\"18700212\" target=\"_blank\">",
"        18700212",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Usala T, Clavenna A, Zuddas A, et al, &ldquo;Randomised Controlled Trials of Selective Serotonin Reuptake Inhibitors in Treating Depression in Children and Adolescents: A Systematic Review and Meta-Analysis,&rdquo;",
"      <i>",
"       Eur Neuropsychopharmacol",
"      </i>",
"      , 2008, 18(1):62-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/17662579/pubmed\" id=\"17662579\" target=\"_blank\">",
"        17662579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/49/15130/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8465 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15130=[""].join("\n");
var outline_f14_49_15130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708805\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172714\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172715\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172763\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172719\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172738\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172720\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172721\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172722\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172686\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172670\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7873368\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7744183\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172690\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172759\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172774\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172761\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172694\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172674\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172756\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172679\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172709\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172681\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172698\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172725\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172699\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172700\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172697\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172683\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172687\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172701\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172673\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172693\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8465\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8465|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/58/30630?source=related_link\">",
"      Fluoxetine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=related_link\">",
"      Fluoxetine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_49_15131="PROVE IT prim endpoint";
var content_f14_49_15131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PROVE IT-TIMI 22 primary end point",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Event rates, percent",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       HR",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Atorvastatin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Pravastatin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       30 days",
"      </td>",
"      <td>",
"       1.9",
"      </td>",
"      <td>",
"       2.2",
"      </td>",
"      <td>",
"       0.83",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       90 days",
"      </td>",
"      <td>",
"       6.3",
"      </td>",
"      <td>",
"       7.7",
"      </td>",
"      <td>",
"       0.82",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       180 days",
"      </td>",
"      <td>",
"       12.2",
"      </td>",
"      <td>",
"       14.1",
"      </td>",
"      <td>",
"       0.86",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       End of follow-up",
"      </td>",
"      <td>",
"       22.4",
"      </td>",
"      <td>",
"       26.3",
"      </td>",
"      <td>",
"       0.84",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Hazard ratios for the primary end point of death from any cause or a major cardiovascular event at 30, 90, and 180 days and at the end of follow-up.",
"    <div class=\"footnotes\">",
"     HR: hazard ratio.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15131=[""].join("\n");
var outline_f14_49_15131=null;
var title_f14_49_15132="Periop complix from IBD meds";
var content_f14_49_15132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of medical therapy for IBD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perioperative complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Prednisone",
"       </td>",
"       <td>",
"        Addisonian crisis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Sulfasalazine",
"       </td>",
"       <td>",
"        Neutropenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood dyscrasias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Azathioprine and 6-mercaptopurine",
"       </td>",
"       <td>",
"        Leukopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macrocytic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow suppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Mesalamine",
"       </td>",
"       <td>",
"        Diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea/vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Metronidazole",
"       </td>",
"       <td>",
"        Convulsive disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cyclosporine",
"       </td>",
"       <td>",
"        Nephrotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        TNF alpha inhibitors",
"       </td>",
"       <td>",
"        Injection site reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infusion reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demyelinating disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induction of autoimmunity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15132=[""].join("\n");
var outline_f14_49_15132=null;
var title_f14_49_15133="Flow waveforms mechanical vent";
var content_f14_49_15133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ventilator flow and pressure waveforms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 145px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Airway pressure (Paw) and flow rate shown for constant, decelerating, and sinusoidal inspiratory flow waveforms. Inspiratory time and tidal volume were held constant. Peak inspiratory airway pressures are similar with all waveforms, but mean airway pressure is highest with the decelerating inspiratory flow wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Banner, MJ, Lanpontang, S, In: Current Respiratory Care, Kacmarek, RM, Stoller, JK (Eds), BC Decker, Philadelphia, 1988.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15133=[""].join("\n");
var outline_f14_49_15133=null;
var title_f14_49_15134="WHO nervous system tumors";
var content_f14_49_15134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO classification of tumors of the nervous system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of neuroepithelial tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Astrocytic tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pilocytic astrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subependymal giant cell astrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleomorphic xanthoastrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diffuse astrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic astrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glioblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gliomatosis cerebri",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Oligodendroglial tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oligodendroglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic oligodendroglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Oligoastrocytic tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oligoastrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic oligoastrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ependymal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subependymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myxopapillary ependymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ependymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic ependymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Choroid plexus tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choroid plexus papilloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atypical choroid plexus papilloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choroid plexus carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other neuroepithelial tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Astroblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chordoid glioma of the third ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiocentric glioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Neuronal and mixed neuronal-glial tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desmoplastic infantile astrocytoma/ganglioglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysembryoplastic neuroepithelial tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gangliocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ganglioglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic ganglioglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central neurocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extraventricular neurocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebellar liponeurocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Papillary glioneuronal tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rosette-forming glioneuronal tumor of the fourth ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paraganglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tumors of the pineal region",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pineocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pineal parenchymal tumor of intermediate differentiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pineoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Papillary tumor of the pineal region",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Embryonal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medulloblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CNS primitive neuroectodermal tumor (PNET)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atypical teratoid/rhabdoid tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of cranial and paraspinal nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schwannoma (neurilemoma, neurinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurofibroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perineurioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant peripheral nerve sheath tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of the meninges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tumors of meningothelial cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meningioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mesenchymal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Adipose tissue:",
"        </em>",
"        Lipoma, angiolipoma, hibernoma, liposarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Fibrous tissue:",
"        </em>",
"        Solitary fibrous tumor, fibrosarcoma, malignant fibrous histiocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Smooth muscle:",
"        </em>",
"        Leiomyoma, leiomyosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Skeletal muscle:",
"        </em>",
"        Rhabdomyoma, rhabdomyosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Cartilage:",
"        </em>",
"        Chondroma, chondrosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Bone:",
"        </em>",
"        Osteoma, osteosarcoma, osteochondroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Vasculature:",
"        </em>",
"        Hemangioma, epithelioid haemangioendothelioma, hemangiopericytoma, anaplastic hemangiopericytoma, angiosarcoma, Kaposi sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ewing sarcoma - PNET",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Primary melanocytic lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diffuse melanocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Melanocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant melanoma, meningeal melanomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other neoplasms related to the meninges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemangioblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lymphomas and hematopoietic neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant lymphomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasmacytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulocytic sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Germinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Embryonal carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yolk sac tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed germ cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of the sellar region",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Craniopharyngioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granular cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituicytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spindle cell oncocytoma of the adenohypophysis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Nervous System. IARC Press, Lyon 2007. Copyright &copy; 2007 IARC Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15134=[""].join("\n");
var outline_f14_49_15134=null;
var title_f14_49_15135="Osteosarc osteoartic allograft";
var content_f14_49_15135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reconstruction of a distal femur defect following resection for osteosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 243px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AP radiograph shows the osteoarticular allograft stabilized with a plate and screws.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis J Hornicek, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_49_15135=[""].join("\n");
var outline_f14_49_15135=null;
